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Abstract 
 
Prostate cancer is the most common malignancy in North American men and there 
is no treatment currently available which offers a clear survival advantage to patients 
with prostate cancer.  We studied liposomes formulated with the fusion-associated 
small transmembrane (FAST) protein, p14.  In this study, we hypothesized that 
therapeutics delivered in molecular targeted fusogenic liposomes will increase 
intracellular delivery and specificity for prostate cancer.  We demonstrated that 
liposomes formulated with p14-bombesin significantly increased the delivery of 
fluorescein isothiocyanate (FITC) into human prostate cancer (PC-3) cells compared 
to either standard liposomes or non-targeted fusogenic liposomes. Delivery of FITC 
to benign prostate hyperplasia (BPH) cells, which express low levels of the gastrin 
releasing peptide receptor (GRPR), was similar for targeted and non-targeted 
formulations. Specificity for GRPR was further established by knocking down GRPR 
expression with siRNA. Knockdown of the receptor resulted in equivalent 
intracellular delivery of the FITC with targeted and non-targeted formulations.    
 
Keywords:  Bombesin, Fusogenic Liposomes, p14, Prostate Cancer, Targeted 
Therapy 
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Chapter 1  
1 Introduction  
1.1 Overview of Prostate Cancer  
 
Epidemiology 
Cancer is a global epidemic and a major health burden with approximately 180,000 new 
cases in Canada alone this year (Canadian Cancer Statistics, 2011).  An estimated 75,000 
Canadians succumbed to this disease in 2011 (Andriole et al., 2009; Canadian Cancer 
Statistics, 2011). The term cancer in lay is a variety of diseases characterized by out of 
control cell growth.  Prostate cancer is the most common cancer in Canadian men with a 
lifetime risk of 1 in 7 and a mortality rate of 1 in 27 (Canadian Cancer Statistics, 2011).  
Prostate cancer is predominately diagnosed between men of 60-69 years of age and if 
diagnosed at an early stage, 98% of cases are curable (Andriole et al., 2009; Canadian 
Cancer Statistics, 2011; Gomella et al., 2011; Jacobsen et al., 1995).  Although prostate 
cancer has been hailed to be a “slow growing cancer”, the incidence rate has increased 
more rapidly in past years (Canadian Cancer Statistics, 2011; Gomella et al., 2011).  This 
increase in diagnosis may be due to the aging population, the evolution of medical 
technology and the routine blood screen for prostate specific antigen (PSA) (Ellison, 
Gibbons, & Canadian Cancer Survival Analysis Group, 2001; Gomella et al., 2011; 
Jacobsen et al., 1995).  Conversely, prostate cancer is also the most common malignancy 
in North American men, accounting for 10% of all cancer-related deaths in 2010 
(Andriole et al., 2009; Ellison et al., 2001).
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Origin 
A cancer of the glandular epithelium, prostate cancer is classified as an adenocarcinoma.  
Prostate cancer risk is determined largely by age however, other risk factors are genetic 
predisposition, dietary habits, and environmental stressors.  Although prostate cancer is 
the most common malignancy in males, the cell of origin in the gland remains unclear.  
Prostate cancer has been thought to arise from cell expansion of luminal cells and the 
absence of basal cells in the epithelium of the prostate gland (Lawson et al., 2010).  
However, recently researchers have identified that basal cells can also initiate prostate 
cancer (Goldstein et al., 2010) and therefore both the basal and luminal cells have now 
been identified as prostate cancer cells of origin (Lawson et al., 2010).  Even though 
prostate cancer is a slow growing cancer it still maintains the ability to metastasize.  Once 
prostate cancer spreads, the cancer predominantly metastasizes to the bone and the lymph 
nodes.  This uncertainty of the biology of the prostate cancer creates uncertainties on how 
to predict the outcome of the disease and therefore how to treat the disease. 
 
Diagnostic Tools  
The current diagnostic tools for prostate cancer are prostate specific antigen (PSA) test, 
Digital Rectal Examination (DRE), biopsy, and Gleason Score (Karakiewicz & Aprikian, 
1998).   The PSA test measures the antigen quantity in the blood serum and men with 
PSA levels between 4.0 and 10 ng/ml are a target population for prostate cancer 
(Jacobsen et al., 1995).  Prostate cancer is a heterogeneous disease that is very commonly 
asymptomatic and thus identification of an increase in PSA levels can identify men with 
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prostate cancer who would otherwise not know (Jacobsen et al., 1995; Ellison et al., 
2001).   While raised serum PSA is a clinically adequate tumour marker, it is not specific 
to prostate cancer, thus it can result in false positives (Ellison et al., 2001).  As mentioned 
above, the PSA test is partially responsible for the increase in incidence rate due to 
identification of prostate cancer in men with localized disease who were asymptomatic 
(Jacobsen et al., 1995).  The PSA test was discovered in the 1980’s and since this time 
the incidence rate has increased because asymptomatic men were diagnosed with prostate 
cancer.  Once the disease is verified by biopsy, sections are graded by the Gleason Score 
which is the only critical test to help decide treatment options (Gomella et al., 2011).  
Due to PSA testing and Gleason scoring, the identification of early disease, the survival 
rate is near 100% (Ellison et al., 2001).   
 
Treatment Options 
As mentioned previously, prostate cancer usually grows very slowly and therefore has a 
low overall risk of turning into a clinically relevant disease, giving rise to the concepts, 
“watchful waiting” (Kasperzyk et al., 2011) and “active surveillance” (Gorin et al., 
2011).  These approaches are for “low risk” patients with a life expectancy of 20 years 
(Gorin et al., 2011).  Radical prostatectomy, or removal of the prostate gland, has 
significant side effects which lowers the quality of life for the patient.  The extraction of 
the entire gland creates an array of life altering complications such a urinary incontinence 
(Doherty & Almallah, 2011) and sexual dysfunction (Siegel et al., 2001).  Taken 
together, surgery is not always the end result in this disease and there is evidence that 
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“active surveillance” can work without adding to the mortality rate (Graversen et al., 
1990).  On the other hand, there is a possibility that an aggressive cancer will be missed 
and the opportunity for a life-saving surgery.  Despite the inherent advantages and 
disadvantages of “active surveillance” and radical prostatectomy (Bangma, 2011), it may 
be safer to intervene and treat the tumour with another means. An alternative therapy 
would be radiation therapy which is the use of ionizing x-ray beams to destroy the 
tumour cells.  However, drawback of this therapy is exposure and degradation of healthy 
cells to ionizing radiation.  Furthermore, chemotherapeutics are small molecule drugs 
which are toxic to all proliferating cells in the body and therefore subject the patient’s 
healthy cells to significant toxicity.  These harmful effects of chemotherapy result in 
unwanted side effects such as hair loss, nausea, and sexual and fertility dysfunction.  
Most chemotherapeutic drugs do not preferentially target the tumour and therefore 
subject the patient’s healthy cells to significant toxicity. Radical prostatectomy and 
radiation is used for localized disease versus chemotherapy treatment for advanced 
prostate cancer (Bangma, 2011; Doherty & Almallah, 2011). No treatment currently 
available offers a clear survival advantage to patients with advanced prostate cancer, 
highlighting the urgent need for new targeted therapeutic strategies.  
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1.2 Liposomes as Therapy Vehicles 
 
Liposomes were first described by Alec Bangham (1964) as spherical lipid particles 
comprised of a phospholipid bilayer enclosing an aqueous core (Bangham & Horne, 
1964).  Due to their intriguing inherent resemblances to cell membranes, liposomes are 
considered universal drug vehicles in the cosmetic and pharmaceutical industries (Drulis-
Kawa & Dorotkiewicz-Jach, 2010).  Liposomes have therefore gone through intense 
research and development to improve drug delivery. Both hydrophobic and hydrophilic 
active molecules can be encapsulated within the liposomal structure due to their unique 
architecture (Liautard et al., 1991).  Hydrophobic molecules are located within the bilayer 
(Schwendener & Schott, 2010) whereas hydrophilic molecules are located in the core of 
the particle (Liautard et al., 1991).  Liposomes are inert, biocompatible particles giving 
rise to the phenomenon of “drug vehicles” to improve the drug pharmacokinetics and 
bioavailability.  The active molecules entrapped in the core can vary from small molecule 
drugs, antibiotics, nucleic acids, and peptides (Drulis-Kawa & Dorotkiewicz-Jach, 2010; 
Lutsiak et al., 2002; Uziely et al., 1995; Yagi et al., 2009).  The unique ability to shield 
the cargo from degradative mechanisms in cells but to also protect healthy cells from 
toxic drugs within makes liposomes an attractive asset to therapeutic delivery (Kaye & 
Richardson, 1979; Mayer et al., 1989).   
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“Stealth” Liposomes 
Decades of research, have been dedicated to improving the bioavailability and tumour 
uptake of liposomes.  To improve the bioavailability, addition of polyethylene glycol 
polymer chain (PEG) molecules are covalently attached to liposomes.  PEGylation 
protects the liposomes from detection of the immune system.  The theory of Stealth ® 
liposomes were first introduced by Allen (Allen et al., 1992) and are considered the 
“second generation” of liposomal drug delivery (Immordino et al., 2006).  Sterically 
stable liposomes increase the pharmacokinetics of the drug and sustain a longer blood 
circulation time (Allen & Hansen, 1991).  PEGylated liposomes are currently in clinics to 
treat a variety of different cancers including breast, ovarian and prostate (Park, 2002), one 
such example is Doxorubicin encapsulated within PEGylated liposomes (commercial 
name: DOXIL) (Allen & Hansen, 1991).  However, it was observed by Mishra et al that 
liposomes functionalized with PEG have been found to decrease endosomal escape 
resulting in degradation of the cargo (Mishra et al., 2004).  While addition of PEG 
molecules to liposomes have a clear benefit on the systemic level, on a cellular level 
PEGylation poses a clear disadvantage (Remaut et al., 2007).  For example, the 
therapeutic index of even these newer “second generation” formulations, is still quite low 
due to non-specific uptake and endocytosis-mediated drug degradation (Figure 1.1A).   
Despite the recent advancements of increasing the drug bioavailability and 
pharmacokinetics, there is still suboptimal delivery of the cargo to inside the cells. 
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1.3 “Fusogenic” Entities 
 
“Fusogenic” Lipid 
Another critical milestone in liposomal development was the introduction of fusogenic 
moieties to avoid endosomal degradation.  Once liposomes are endocytosed, the particles 
are challenged by the acidic environment and thereby an escape mechanism is needed to 
salvage the cargo they carry.  The simplest method is incorporation of a “fusogenic” 
lipid, such as a neutral helper lipid phosphatidylethanolamine (PE) (Farhood et al.,1995; 
Zhou & Huang, 1994).  Several groups have shown that addition of 1, 2-dioleoyl-sn-
glycerol-3 phosphatidylethanolamine (DOPE) in their liposomes will significantly 
increase the transfection of deoxyribonucleic acid (DNA) (Farhood et al., 1995; Zhou & 
Huang, 1994).  Zhou and Huang reported the presence of DOPE increases the DNA 
transfection by 60% compared to liposomes without DOPE (Zhou & Huang, 1994).  The 
authors also reported that the DNA entered the cytoplasm mainly by destabilizing 
endosomes and provoking endosomal escape (Zhou & Huang, 1994).   Furthermore, 
Farhood et al demonstrated that this endosomal release was only in the presence of high 
levels of DOPE (Farhood et al., 1995).  In extension of these studies, DOPE was 
characterized to have a cone-like structure which adopts a hexagonal phase that disrupts 
the endosomal membrane and initiating the escape into the cytoplasm (Zuhorn et al., 
2005).  Taken together, DOPE acts as an endosomolytic agent depositing the cargo into 
the cytosol of cells. 
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“Fusogenic” Peptides 
Efforts have been made to mimic methods employed by viruses for intracellular delivery 
of macromolecules (Kobayashi et al., 2009).  Studies have been reported using a variety 
of pH sensitive peptides such as vesicular stomatitis virus proteins, phage coat proteins 
proteins and shGALA to name a few (Peisajovich et al., 2002; Sakurai et al., 2011).  
These viruses have evolved as an effective strategy to escape the endosomal uptake of 
compounds by exploiting biological processes.  There are many fusogenic peptides that 
can traffic membrane impermeable compounds into the cell by endocytosis, however 
only limited studies have been accomplished to incorporate these proteins within 
liposomes.    
VSV G protein 
Previous research has successfully reconstituted an enveloped viral protein, vesicular 
stomatitis virus (VSV) glycoprotein (G) protein within liposomes using Octylglucoside 
(OG) dialysis (Eidelman, 1984; Metsikko, 1986; Petri, 1979).  Petri et al was the first to 
describe the insertion of the VSV G protein within a lipid bilayer using the OG detergent 
depletion.  In extensions of this study, to evaluate the fusogenic capabilities, other groups 
discovered that the fusion was pH dependent (pK~4.0) and therefore the entry within 
endosomes was needed for the G protein to exert its effect (Eidelman et al., 1984).   
Furthermore, it was observed that, upon detergent dialysis using SM2 beads to remove 
the detergent, the G protein loses fusion activity (Metsikko et al., 1986).  The authors 
speculate that the hydrophobic beads caused denaturation of the G protein (Metsikko et 
al., 1986).  Despite these inherent advantages of rapid endosomal release, the key strategy 
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for improved efficiency of liposomal therapeutics would be to penetrate the cell 
membrane bypassing endocytosis. 
Phage Coat Protein 
Phage coat proteins are examples of fusion proteins which increase the intracellular 
escape from endosomes (Wang, et al., 2010).  Recent studies, using a phage coat library 
technique, have identified PVIII protein with specific fusion abilities toward targeted 
cells (Jayanna et al., 2009).  It was observed through fluorescence microscopy, that phage 
liposomes were taken up by endocytosis and triggered membrane fusion in the endosomal 
acidic environment (Wang et al., 2010).  The authors compared their phage liposomes to 
plain liposomes and visualized the perinuclear punctuate localization of the standard 
liposomes compared to the diffuse distribution of the phage liposomes.  The authors 
postulated that the diffuse pattern was a result of endosomal escape through fusion of the 
pH sensitive phage proteins to the endosome bilayer (Wang et al., 2010).  Furthermore, 
they verified this theory by adding an endosome acidification inhibitor (NH4CL) and 
observed the entrapment of the phage liposomes within perinuclear vesicles (Wang et al., 
2010).  Thereby, confirming the pH sensitive phage liposomes elicit their fusion 
capabilities in the acidic endosomal environment to release their cargo intracellularly. 
Despite the success of inserting these fusogenic peptides into liposomes, unsuccessful 
fusion with the cell membrane was observed.  These endosomal release strategies using 
enveloped viruses increased the intracellular delivery compared to standard liposomes 
however, the results are sub-optimal and the ultimate goal of fusion with the cell 
membrane was not successful. 
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1.4 P14 Liposomes 
Orthoreovirus Non-enveloped Fusion Proteins 
Fusion associated small transmembrane (FAST) proteins are a unique class of proteins 
encoded by the genus orthoreoviruses.  The five distinct species in the orthoreoviruses 
genera include the avian reovirus (ARV), nelson bay reovirus (NBV), and baboon 
reovirus (BBV), aquareovirus reovirus (AQV) and reptilian reovirus (RRV) (Duncan, 
Murphy, & Mirkovic, 1995; Duncan et al., 2004; Gard & Compans, 1970; Shmulevitz & 
Duncan, 2000).  Reoviruses represent a distinct group of non-enveloped viruses that are 
capable of forming multinucleated cells, syncytia (Duncan et al., 1996; Duncan et al., 
2004; Shmulevitz et al., 2003; Shmulevitz et al., 2004; Top et al., 2011).  Fusogenic 
reoviruses are a rare exception of non-enveloped viruses which induce cell-cell fusion 
independent of virus entry and production (Duncan et al., 1996; Duncan, 1996; 
Shmulevitz & Duncan, 2000).  A typical phenotype for enveloped viral proteins promotes 
entry of the virus into cells (Shmulevitz & Duncan, 2000).  Upon infection of these 
reoviruses, fusion associated small transmembrane (FAST) proteins are translocated to 
the cell surface mediating cell-to-cell fusion (Shmulevitz & Duncan, 2000; Shmulevitz et 
al., 2002). 
The classification of the reptilian reovirus was recorded by Duncan et al as a distinct 
species of the fusogenic reoviruses (Duncan et al., 2004).  Even though the reptilian virus 
was discovered and isolated years before from a moribund python in 1987 (Ahne, 
Thomsen, & Winton, 1987), the virus was never classified as a new fusogenic species at 
that time.   Duncan et al established the newly identified reovirus after confirming the 
virus induced extensive multi-nucleated cells (syncytium) in infected cell cultures typical 
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of fusogenic reoviruses.  Furthermore, the 125 amino acid fusion protein had differential 
sequences compared to the other FAST proteins. 
 
P14 FAST Protein Structure 
The reptilian reovirus FAST protein was named according to the molecular weight in 
kDA, p14.  The authors characterized the structural motifs of the p14 protein and 
revealed its own signature arrangement of a myristoylated N-terminus; however the 
protein remains surface-localized (Corcoran & Duncan, 2004).  Figure 1.2 illustrates the 
structure of the p14 FAST protein, highlighting the N-terminal myristoylation site, the 
hydrophobic path, a single transmembrane domain, and the exposed C-terminus.  Further 
studies indicated that the myristoylation of the N-terminal region was responsible for the 
fusion capabilities (Corcoran & Duncan, 2004; Corcoran et al., 2004).  It was 
demonstrated that point mutations at the myristoylation site renders the p14 fusion 
incompetent (Corcoran et al., 2004).  Moreover, to confirm the N-terminal myristoylation 
site was solely responsible for the fusion abilities, deletion of the C-terminal 10-20 amino 
acids was evaluated.  Overall, the extent of fusion remained unaltered, however the rate 
of syncytium was slowed (Corcoran et al., 2004).  Taken together these results confirm 
that the post translational modification of p14 is both functional and essential for fusion 
activity (Corcoran et al., 2004). 
 
 
12 
 
 
 
Figure 1.1 Representation of Intracellular Cargo Delivery Using Liposomes  
A) Standard liposomal technology depends on two routes for intracellular delivery; i) 
non-specific leakage of the cargo out of the liposome and passive uptake by the target 
cells or ii) uptake of intact liposomes into the endosomal pathway.  
B) Fusogenic liposomes include the p14 FAST protein which mediates efficient 
liposome-cell fusion, bypassing the endocytic pathway, depositing the cargo directly into 
the target cell.  The fusogenic liposomes therefore have a distinct advantage over the 
standard liposomes when delivering cargo intracellularly.  
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P14 Reconstituted into Liposomes  
In an extension of these studies, the authors tested whether p14 protein could function on 
its own to induce membrane fusion when reconstituted in liposomes (Top et al., 2005).  
The p14 protein was inserted into the artificial bilayer using OG detergent depletion 
method (Petri & Wagner, 1979).  The authors identified the equal protein orientation by 
immunofluorescence staining of both the exposed N-and C-terminus (Top et al., 2005).  
The theory proposed by the authors is that exposure of the p14 N-terminal myristoylation 
on the surface of the liposomes allows the p14-liposomes to interact with cell membrane 
of target cells (Figure 1.1 B). Figure 1.1 demonstrates the comparison of cargo uptake 
between the standard and fusogenic liposomes.  The successful intracellular delivery of 
the cargo using standard liposomes is based upon i) non-specific leakage of the 
encapsulated cargo in the bloodstream and passive uptake by the target cells and ii) 
uptake of the intact liposomes into the endosomal pathway (Figure 1.1A).  The cargo 
contained within standard liposomes is prone to degradation upon entry into the 
endocytic pathway. For this reason, the standard liposomes are restricted to specific 
cargos that posses inherent membrane penetration capabilities and the ability to withstand 
the acidic environment of the endosomal pathway.   However, it is hypothesized that 
fusogenic liposomes fuse with the cell membrane via the N-terminal myristoylation site 
allowing lipids from the cell membrane and liposomes to mix, for direct deposit into the 
cell (Figure 1.1B) (Top et al., 2005).   
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Figure 1.2 Schematic representing the fusogenic liposomal platform  
A) The structure of p14 Fusion Associated Small Transmembrane (FAST) protein.  The 
p14 protein is encoded by the reptilian reovirus (RRV) and is named according to the 
molecular weight in kDa.  The 125 residue structure contains; N-terminus myristoylation 
site (green triangles), the hydrophobic patch (yellow half circle), transmembrane domain 
(purple rectangle), basic region (blue rectangle) and the C-terminus polyproline motif 
(red half circle). Reprinted from (Corcoran & Duncan, 2004; Top et al., 2005).   
B) Representation of fusogenic liposomes; p14 spans the lipid bilayer displaying either 
the N- or C- terminus on the surface of the liposome.  The green circles represents the 
“cargo” (example in this thesis: fluorescein isothiocyanate (FITC)) encapsulated within 
the core of the liposome.   
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P14 Induces Lipid Mixing with the Cell Membrane 
To test the lipid mixing hypothesis, Top et al performed a FRET, (fluorescence resonance 
energy transfer) assay and measured the fluorescence by flow cytometry (Struck et al., 
1981; Top et al., 2005).  The increased cell fluorescence over time was observed with 
p14-liposomes whereas this increase was not observed with standard liposomes (Top et 
al., 2005).  To ensure these results were due to lipid mixing, the authors added 
lysophosphatidylcholine, a monoacylated fatty acid known to inhibit membrane fusion 
(Chernomordik & Kozlov, 2003; Top et al., 2005).  The addition of 
lysophosphatidylcholine efficiently inhibits lipid mixing of the p14-liposome and the 
cells, confirming the lipid mixing hypothesis (Top et al., 2005).  The exceptional 
structural features of p14 initiate liposome-cell lipid mixing identifying a potential 
liposomal carrier which bypasses endocytosis. 
   
P14 Liposomes Intracellular Delivery  
Cytoplasmic delivery of therapeutics is highly desirable, however very difficult to 
achieve because poor performance of standard liposomes and previously described 
fusogenic peptides.  The ideal delivery system would bypass the endocytic pathway and 
deliver the cargo directly to the cytosol of cells.  The unique feature of the p14 FAST 
protein has the potential to solve this drug delivery caveat.  Mader et al demonstrated the 
ability to deliver a cytotoxic peptide directly to the cell cytoplasm via p14-liposomes 
(Mader et al., 2007).  Bovine lactoferricin (LfcinB) is a cationic peptide that kills 
leukemia cells.  In the presence of endocytosis inhibitors, LfcinB on its own was not 
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internalized by receptor mediated endocytosis (Mader et al., 2007).  However, when 
LfcinB was delivered using p14-liposomes, the release was directly into the cytosol 
causing cell death (Mader et al., 2007).  The extensive studies on p14 and how it interacts 
within a lipid bilayer has given critical insight into a novel fusogenic liposome that does 
bypass endocytosis, however penetrates the cell membrane. 
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1.5 Passive Targeting 
Another interesting property of liposomes is their natural ability to accumulate at the 
tumour site.  Healthy, normal blood vessels are comprised of endothelial cells that are 
bound together by tight junctions and therefore inhibit large particles from leaking out of 
the vessel.  Consequently, the tight junctions of tumour vessels are compromised and 
particles are able to leak through the leaky cell fenestrations.  This process of passive 
targeting occurs because of the various anatomical anomalies that occur in tumour 
vessels, such as leaky vasculature and poor lymphatic drainage, termed enhanced 
permeability and retention effect (EPR) (Matsumura & Maeda, 1986).  Matsumuri et al 
studied the EPR effect by testing the accumulation of macromolecules in tumour tissue 
upon intravenous injections of radioactive labeled protein in a mouse model (Matsumura 
& Maeda, 1986).   The authors were able to identify the collection of labeled 
macromolecules in the subcutaneous tumours and concluded that the vasculature near the 
tumour had been compromised and these macromolecule accumulations were due to 
passive targeting of the EPR effect (Matsumura & Maeda, 1986).   A key consideration 
for the design of nanocarriers to take full advantage of the EPR effect is the size of the 
particle (Yu et al., 2010).  It was identified that particles of < 200 nm in diameter are the 
preferred size to rapidly accumulate at tumour sites via the EPR effect (Liu et al., 1992).  
Furthermore, PEGylated liposomes reduce the recognition by the RES and long 
circulating liposomes are required for extravasation (B. Yu et al., 2010).   
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Taken together, liposomes were shown to extravasate and accumulate selectively in 
tumour interstitium of a variety of murine models as a result of EPR effect.  Figure 1.3 
demonstrates the differences between liposome accumulations in tumour versus normal 
vasculature, highlighting the effects of the EPR effect.  Therefore, liposomes could 
accumulate over time in solid tumours after intravenous administration.  Moreover, 
current anti-cancer therapeutics, such as DOXIL®, are passively targeting tumours and 
by virtue of the EPR (Kuijpers et al., 2000).  However, passive targeting cannot promote 
further uptake by cancer cells once they have arrived.  Therefore, further investigation of 
targeted receptor mediated uptake would increase the therapeutic window of anti-cancer 
drugs.   
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Figure 1.3  Schematic of the enhanced permeability and retention effect (EPR) 
Normal vasculature permits liposomes to pass between the endothelial cells, whereas the 
EPR effect results in leaky vasculature where liposomes <200 nm in diameter can pass 
between the junctions and act on the cancer cells. 
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1.6 Active Targeting 
“Smart Particles” or “Magic Bullets” are terms coined for the phenomenon that 
therapeutics can selectively target and kill cells without harming the neighboring cells. 
Direct targeting of cancer cells using liposomes has the potential to treat cancer with 
higher efficiency than standard anti-cancer therapeutics. There are key points to consider 
when creating targeted nanoparticles; 1) a target should be in sufficient quantity 
(overexpressed) providing a good opportunity to bind to the target 2) ligand attachment 
should be attached to the surface of the particle and 3) a target should facilitate 
internalization (Maruyama, 2011).   
 
Prostate Targeting Ligands 
Direct targeting of prostate cancer is a strategy towards killing the cancerous cells while 
decreasing healthy bystander cell toxicity.  Various types of targeting ligands have been 
exploited for directing liposomes to prostate cancer (Table 1.1).  Attention has been 
directed towards targeting liposomes to cell integrins, as they have significant expression 
on tumour vasculature.  Such peptides that would bind to αvβ3 and α5β1 integrins are 
promising ligands to target a variety of different cancers, including prostate (Arap et al., 
1998; Demirgoz et al., 2008).   Demirgoz et al examined the targeted efficiency of the 
PR_b functionalized liposomes to α5β1 integrins (Demirgoz et al., 2008).  The authors 
demonstrated that liposomes functionalized with PR_b improved the cytotoxicity 
displayed by the total higher fluorescent intensity for prostate cells in stages of apoptosis 
(Demirgoz et al., 2008).  Despite recent advancements with targeting the αvβ3 integrins 
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with RGD decorated liposomes, the studies using PR_b liposomes demonstrated a clear 
advantage over the RGD targeting techniques (Demirgoz et al., 2008).   Other, attractive 
targets for cancer are the transferrin and folate receptors as they are both highly up 
regulated on tumours (Gabizon et al., 1999; Singh, 1999; W. Yu et al., 2004).  While 
these ligands target a variety of different cancers, the anti-PSMA ligand is specific for 
prostate cancer.  Expressed on the surface of prostate cancer cells, the prostate specific 
membrane antigen is used in targeted delivery.   Ikegami et al constructed liposomes 
containing anti-PSMA for targeting gene therapy and concluded that the transfection was 
higher in the targeted liposomes than that of normal liposomes (Ikegami et al., 2006).  
There are many different targeted ligands that can be conjugated to the surface of 
liposomes; however, it is the method on which the ligand is supported that will prove to 
be efficient. 
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Table 1.1  Prostate Cancer Targeting Ligands for Liposomes  
Type Targeting  
Ligand 
Receptor References 
Peptide  RGD 
PR_b 
αvβ3 
α5β1 
 
(Arap et al., 1998) 
 (Demirgoz et al., 2008) 
Protein Transferrin 
 
 
Transferrin 
Receptor 
 
(Singh, 1999; W. Yu et al., 
2004) 
Antibodies Anti-PSMA  PSMA Receptor (Ikegami et al., 2006) 
Small 
Molecules 
Folic Acid Folate Receptor (Gabizon et al., 1999) 
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Attachment of the Targeting ligand 
The construction of a targeted particle requires the conjugation of the ligand to the 
surface of the liposomes.  The two methods deployed for the attachment of ligands are 
either covalent or noncovalent coupling (Nobs et al., 2004).  Ligands can either be 
assembled with phopholipid headgroups of non-PEGylated liposomes or can be anchored 
to the liposomes via PEGylated chains (Maruyama, 2002; Sofou, 2007). Different 
covalent coupling strategies include thioether bonds, disulfide linkage, crosslinking, and 
hydrazone bond (Hansen et al., 1995; Nobs et al., 2004).  Despite these efforts to attach 
ligands to the surface of liposomes, there is not an optimal covalent coupling reaction.  
This is due to the drawbacks of the number of crucial parameters, such as the length, type 
and localization of the crosslinker.  Covalent reactions also require chemical reagents 
which could potentially alter or damage the ligand or the liposome (Hansen et al., 1995).  
Non-covalent coupling is beneficial over covalent coupling because there is no need for 
harsh chemicals (Nobs et al., 2004).  However, this method is not widely used because of 
the weak interaction of ligand on the liposomal surface (Duarte et al., 2011; Nobs et al., 
2004). Therefore, targeted proteins that can be inserted into the bilayer of the liposomes 
would be optimal, due to these drawbacks of coupling to the surface of the liposomes. 
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1.7 Bombesin Targeting Peptide 
The development of anti-cancer therapeutics that can be targeted to specific receptors, 
over-expressed in prostate cancer, but sparse the uptake in normal tissue, is critical.  
Receptors for the gastrin releasing peptide are over-expressed in several human tumours, 
including pancreatic, small lung carcinoma, breast, and prostate (Varvarigou et al., 2004).  
Originally isolated from the skin of the fire bellied frog Bombina bombina, Bombesin is a 
14 amino acid peptide (Anastasi et al., 1971).  Although the GRPR is frequently 
expressed by many tumour types there are three other bombesin receptor subtypes that 
bombesin binds to, NMB, BRS-3, and BB4 (Reubi et al., 2002).   Furthermore, prostate 
cancer cells express approximately 48000 GRPR per cell (Aprikian et al., 1996).  Many 
radiolabelled bombesin analogues have been created for SPECT and PET modalities to 
target the GRPR, allowing for novel prostate cancer imaging probes (Ananias et al., 
2008; Safavy et al., 1997).  Even though there have been no studies performed 
conjugating bombesin to liposomes there has been however, bombesin attachment to 
polymeric (Lee et al., 2010) and viral nanoparticles (Steinmetz et al., 2011).  Current 
studies in our laboratory have demonstrated the tumour homing efficiency of bombesin 
virus particles by intravital imaging in a xenograft avian embryo model of human 
prostate cancer (Steinmetz et al., 2011).  We validated bombesin targeting to a human 
prostate cancer cell line (PC3) in vitro by confocal microscopy.  Non-targeted viral 
nanoparticles did not bind to PC3 cells at an appreciable level compared to bombesin 
particles (Steinmetz et al., 2011).  To ensure that binding of the bombesin particles was 
specific for the GRPR a 10-fold excess of free bombesin peptide was added to block the 
particles, resulting in a dramatic decrease in bombesin-viral uptake (Steinmetz et al., 
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2011).  This previous research in our laboratory suggests that bombesin would be suitable 
for functionalizing liposomes to target prostate cancer.  
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1.8 Nucleic Acid Delivery Using Liposomes 
Liposomes have been used as carriers for many different applications and are not limited 
by the cargo they carry.  As mentioned previously, nucleic acids can also be packaged 
within liposomes to improve the delivery of deoxyribonucleic acid (DNA) and small 
interfering ribonucleic acid (siRNA).  Traditional transfection reagents such as 
Lipofectamine™ are some of the most popular transfection reagents utilized for in vitro 
as they are comprised of a cationic lipid, 1-2, 3-dioleyloxy-propyl- trimethylammonium 
chloride (DOTMA) (Felgner et al., 1987). Cationic formulations facilitate the functional 
delivery into cells as they complex with the negatively charged nucleic acids.  These 
traditional transfection reagents however, cannot be used in vivo because they are 
unstable in plasma and are eliminated rapidly from the blood.  Consequently, neutral 
liposomes have been used instead.  However, their encapsulation efficiency is low.  Thus, 
the development of a liposomal carrier that provides physical containment of the nucleic 
acids is needed to overcome the problems associated with existing cationic carriers (Yagi 
et al., 2009). 
 
Wrapped Liposomes 
The development of novel liposomes “Wrapsomes” (WS) or “Wrapped Liposomes” 
(WL) were constructed using an innovative procedure (Yamauchi et al., 2006).  The 
strategy was to increase the nucleic acid encapsulation efficiency by identifying an 
alternative liposomal formulation (Yamauchiet al., 2006).  Complexes were prepared by 
incorporating a cationic lipid core in order to complex with the siRNA within a neutral 
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liposomal bilayer to increase the serum stability (Yamauchi et al., 2006).  Yagi et al also 
adopted this unique lipid formulation and proved that WS nanoparticles stabilize siRNA 
decreasing the degradation in serum (Yagi et al., 2009).  The authors also evaluated the 
WS uptake in vivo and reported inhibition of tumour growth (Yagi et al., 2009).  
Wrapped liposomes are the first to our knowledge to demonstrate efficient nucleic acid 
delivery in vivo. 
 
Heparin Releases DNA from Liposomes  
The strong interaction with cationic lipids to DNA creates difficulty when quantifying 
DNA encapsulation within liposomes (Gershon et al., 1993).  Using conventional 
methods for quantifying DNA, such as Ethidium Bromide (EtBr), results in a decrease of 
intercalation because the cationic lipids displace the binding of the agent.   In this 
vicinity, a compound needs to be added to substitute the lipids from the DNA before 
DNA quantification is performed.  Addition of anionic polymers, such as heparin and 
dextran sulfate, is commonly used to displace the cationic lipids from the DNA (Tsai, 
Furstoss et al., 2002; Xu & Szoka, 1996; Zelphati & Szoka, 1996).  Anionic polymers 
have a 2 fold greater charge density than DNA which explains why cationic lipids 
preferentially associate with the polymers over DNA and quantification can be performed 
(Casu, 1985).  Previous studies demonstrated that heparin and dextran sulfate 
substantially released plasmid DNA (>50%) from cationic liposomes before quantifying 
with EtBr (Xu & Szoka, 1996; Zelphati & Szoka, 1996).   
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1.9 Hypothesis and Objectives  
Given the structure of p14, we hypothesize that the incorporation of bombesin targeting 
peptide will be tolerated at the C-terminal end of p14, so that liposomes with cell-specific 
and fusogenic properties will increase the intracellular delivery of therapeutics and 
specificity for prostate cancer. 
In this dissertation my objectives are as follows: 
1) Establish the intracellular delivery of liposomes formulated with p14 protein (non-
targeted) 
a) Calculate the syncytia index of p14 expression in human fibrosarcoma 
(HT1080) cells 
b) Determine the p14 localization in syncytium formation 
c) Verify the fusogenic liposome platform by comparing the intracellular delivery 
of FITC compared to standard liposomes in human breast cancer (MDA-MB 
231), human fibrosarcoma (HT1080), and prostate cancer (PC3) cells 
2) Create a targeted fusogenic protein by conjugating bombesin to the C-terminus of the 
p14 to target the gastrin releasing peptide receptor overexpressed on prostate cancer  
a)  Generate a p14-bombesin plasmid and test the functionality using a fusion 
assay  
c) Create a recombinant baculovirus to purify the p14-bombesin protein and 
verify the active protein  
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3) Assemble p14-bombesin liposomes and assess the delivery of fluorescein 
isothiocyanate (FITC) to prostate cancer cells 
a)  Insertion of the active proteins and test the uptake of the targeted liposomes on 
PC3 cells  
4) Evaluate the specificity of the targeted fusogenic liposomes  
a) Evaluate the uptake of p14-bombesin liposomes on benign prostatic 
hyperplasia (BPH) cells  
 b) Receptor blocking analysis 
 c) Knockdown of the GRPR using siRNA 
5) Evaluate the intracellular delivery of nucleic acids 
 a) Encapsulate plasmid DNA using a novel wrapped liposomes carrier 
 b) Calculate the entrapment efficiency of the DNA within the WS 
 b) Assess the transfection efficiency of the p14-wrapsomes containing GFP 
 
The preliminary results from the targeted fusogenic liposomes developed here indicate 
the novelty and the specificity of this therapeutic vehicle for prostate cancer.  Although 
the data is ongoing, it provides a basis for a therapeutic carrier with the ability to increase 
the therapeutic efficacy of small molecule drugs and nucleic acids.  The efforts made here 
contribute to the overall goal to deliver therapeutics to prostate cancer using the platform 
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developed in this dissertation.  The fifth objective was to establish the efficacy of nucleic 
acid delivery.  However, the results for plasmid DNA delivery are preliminary and the 
sample size is small.  The data included in this thesis is a means to show the potential of 
such a platform for different uses.   
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Chapter 2  
2 Materials and Methods 
 
Cell culture 
Spodoptera frugiperda insect cells (sf21) purchased from ATCC were grown in either a 
monolayer or in suspension.  Adherent sf21 cells were grown in Graces 1x media (Gibco) 
supplemented with 10% fetal bovine serum (FBS) (Multicell), L-Glutamine (Multicell) 
and 10, 000 IU/ml penicillin and streptomycin (Invitrogen) at 27
 o
C.  The suspension sf21 
cells were grown in SFII 900 (Gibco) media supplemented with 3% FBS at 27
 o
C and 
rotated at 127 RPM.  All of the following cells were purchased from ATCC; MDA-MB 
231 Breast Cancer, Human Fibrosarcoma (HT1080) and HT1080 cell stably transfected 
with td-tomato (HT1080td-tom), and Prostate Cancer (PC3).  MDA-MB 231 and 
HT1080/td-tom were grown in a monolayer with Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Multicell) and PC3 cells were grown in F12K media (Multicell). The above 
medium was supplemented with 10% FBS and 10, 000 IU/ml penicillin and streptomycin 
and incubated at 37
o
C in a humidified 5% CO2 atmosphere.  Benign Prostatic Hyperplasia 
(BPH) cells were a generous gift from Dr. Michael Cox, VGH) were grown as 
monolayers in low FBS 5% DMEM in the same conditions as the MDA-MB 231, 
HT1080 and PC3 cells. Quail Fibrosarcoma Muscle cells (QM5) cells were isolated and 
cultured in M199 media as described by Tran et al., (Tran et al., 2009). 
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Antibodies 
The following antibodies were used in this study: β tubulin mouse mAb (SIGMA), 
Gastrin Releasing Peptide Receptor (GRPR) rabbit mAb (Abcam), and p14 rabbit mAb (a 
gift from Dr. Roy Duncan’s lab). 
 
Western Blot Analysis 
For analysis of GRPR, 80% confluent cultures of PC3, PC3 knockdown and BPH cells in 
6 well plates were washed twice with 1x phosphate buffered solution (PBS) and detached 
from the dish with a sterile cell scraper. Samples were collected into microcentrifuge 
tubes and  centrifuged at 14000 rpm for 5 minutes and then lysed with cold NP40 lysis 
buffer (1 % NP-40, 50mM Tris-HCL, pH 8.0, 150 mM NaCl) containing protease 
inhibitor cocktail (Roche) for 10 minutes on ice, centrifuged for another 14000 rpm for 
10 minutes.  Protein was collected and the concentrations were measured by the Bradford 
protein assay (BioRad).  10 µg of total protein was denatured in DL-Dithiothreitol (DTT) 
(Sigma-Aldrich) at 95
o
C for 5 min and was loaded into 12 % gels, separated using SDS-
PAGE gels and transferred to a polyvinylidene difluoride (PVDF) membrane (GE 
Healthcare).  Membranes were blocked for1hr at room temperature in 5% skim milk 
(Bioshop) in TBST (10mM Tris base pH 7.4, 150mM NaCl, and 0.1% Tween 20).  To 
probe for rabbit GRPR pAb (1:500), the rabbit p14 pAb (1:1000) or mouse β tubulin 
mAb (1:1000) in 5% skim milk in TBST was placed on the membrane overnight at 4
o
C.  
After three washes of TBST, horseradish peroxidase conjugated secondary antibody, 
either anti-rabbit or anti-mouse (1:10,000 in 5% skim milk in TBST) (GE Healthcare) 
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was incubated1hr at room temperature followed by five washes with TBST.  The 
presence of protein was evidenced by using the enhanced chemiluminescence (ECL) 
detection kit (GE Healthcare). All bands were quantified by densitometry using Image J 
gen analysis took and expression was reported relative to Tubulin expression. 
 
Creation of recombinant p14-bombesin 
A recombinant baculovirus encoding p14-bombesin was created using the Bac-To-Bac 
Baculovirus Cloning and Expression System (Invitrogen).  Bombesin was cloned into the 
pFastBac1-p14 (generous gift from Roy Duncan (Top et al., 2005) transfer vector by 
PCR amplification under the control of the polyhedrin promoter between the restriction 
enzyme (RE) cleavage sites BamH1 and Xho1 (NEB). The following primers (Forward:  
5’-GCGGATCCATGGGGAGTGGACCCTCTAATTTCG - 3’; Reverse:  5’-
GCCTCGAGTTACATCAAGTGACCCACTGCCCAACTGATTCCCCAGCCTCTGCT
CGTGATGGTGGTGATGGTGCTTGTTCGTCGTCATC-3’) purchased from Sigma 
was incorporated an in-frame enterokinase-cleavable C-terminal 6x histidine tag, the 
entire bombesin sequence, and restriction sites for BamH1 and Xho1 into the PCR 
product for insertion into pFastBac1-p14.  After purification (Bio Basic Inc. Gel 
extraction and PCR product purification kits) and enzymatic digestion with BamH1 and 
XHO1 (NEB), the construct was ligated into pFastBac plasmid under the control of the 
polyhedrin (PP) promoter, sequenced and transiently expressed into HT1080 cells.  The 
sequences were confirmed by DNA sequencing analysis at Robarts Research Institute. 
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Plasmid Fusion Assay 
HT1080td-tom and QM5 cells were seeded in 12 well plates to 70-80% confluency in 
DMEM and M199 media containing 10% FBS for 24 hours.  The pFastBac-p14 and 
pFastBac-p14-bombesin were incubated with Lipofectamine 2000 (Invitrogen) as 
recommended by the manufacturer and added to cells in a ratio of 1 µg of DNA: 2 µl of 
Lipofectamine 2000 in serum free conditions and incubated at 37
o
C.  After 4 hours media 
was replaced with serum containing DMEM and M199.  At the 8-10 hour time point the 
HT1080td-tom cells were analyzed using fluorescent microscopy.  The QM5 cells were 
stained with CellTracker™ Green (Invitrogen) following manufacture guidelines and 
visualized using epifluorescence microscopy.  The QM5 cells were also analyzed using a 
flow cytometry (Union Biometric) and staining the nuclei with SYTOX® green. The 
QM5 cells were detached from the surface using trypsin (Gibco) and cell suspensions 
were centrifuged for 1400 rpm for 5 minutes.  Cell pellets were resuspended in 1X PBS, 
centrifuged for another 1400 rpm for 5 minutes before cells were fixed using 4% 
formaldehyde (Bioshop) solution in 1X phosphate buffered solution (PBS) for 10 minutes 
on ice.  Fixed cells were centrifuged for 5 min at 1400 rpm.  The fixative solution was 
then discarded and the pellet was washed 2x with 1X PBS.  The cell pellet was stained 
using SYTOX® green (Invitrogen) according to manufacturing guidelines.  The cell 
pellet was resuspended in PBS + 2% FBS and analyzed using flow cytometry.  
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Recombinant p14-bombesin Baculovirus  
Following the Invitrogen’s Bac-to Bac Baculovirus Expression systems, DH10αBac 
Escherichia coli (E.coli) (Invitrogen) cells contain a baculovirus shuttle vector (bacmid).  
Site-specific transposition of the pFastBac1-p14- bombesin expression cassette into the 
bacmid creates a recombinant baculovirus that was isolated from E.coli using standard 
mini-prep kit (Qiagen), and subjected to (0.5%) agarose gel electrophoresis for 1-2 hours 
at 125 volts. PCR analysis of the transposition region of the recombinant bacmid using 
M13/pUC forward and reverse primers (Life Technologies) was used to confirm insertion 
of the p14-bombesin open reading frame.  The mini-prep p14-bombesin bacmid DNA 
and Cellfectin® (Life Technologies) in sf21were used to transfect 4 x 10
6
 sf21 cells for 5 
hours at 27 C.  The transfection medium was removed and replaced with sf21 
supplemented with 10% (FBS).  After 3 days at 27 C, the recombinant baculovirus-
containing supernatant was harvested and passaged 3 times in Sf21 cells. 
 
Plaque Assay 
The recombinant p14-bombesin baculovirus titer was obtained by the plaque assay 
following the Bac-to-Bac recombinant guidelines (Invitrogen).  The plaque assay is used 
to determine the viral titer as plaque forming units per ml (pfu/ml), in order to determine 
the amount of virus used to infect insect cells for protein production.  Healthy (>95 % 
viable) adherent sf 21 cells were seeded in 6 well plates (2 x 10
6 
cells) and allowed to 
adhere for 1hr.  Cell monolayers were infected with viral serial dilutions of low ratio p14-
bombesin virus and an overlay of agarose medium mixture (Grace’s 2x Insect media 
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(Gibco), 10% FBS and low grade 4% agarose (Bioshop)) was added to the monolayers to 
keep the cells stable and limits the spread of virus.  Once the agarose medium has 
solidified, plates were placed in a humidified chamber for 5-10 days.  Plaques (or 
clearings in the monolayer were visualized by inverting the plates.  When an infected cell 
produces virus it eventually lyses and thus only adjacent cells become infected.  Each 
group of infected cells is called a plaque, or a clearing in the monolayer of sf21 cells.  
Each plaque represents a single virus and thus the virus can be counted to determine the 
viral titer (pfu/ml) of the virus stock.   
 
Protein Purification 
Sf21 cells were grown in 3L suspension cultures to a cell density of approximately 4 x 
10
6
/ml and then infected with recombinant baculovirus at a MOI of 0.05 to 2.0, and 
shaken 127 RPM.  At 24 or 48 h post-infection (~20% dead cells), infected cells were 
harvested and centrifuged at 150 x g for 20 minutes at room temperature.  The resulting 
cell pellet was lysed with extraction buffer (50 mM sodium phosphate, 300 mM NaCl, 
1.6% Igepal, and pH 7.0) plus protease inhibitors (200 nM aprotinin, 1 μM leupeptin, and 
1 μM pepstatin).  Insoluble debris was pelleted and the supernatant, containing p14 or 
p14-bombesin, was then added to TALON® Metal Affinity Resin (Clontech) and shaken 
gently for 3 hours at 4
o 
C for initial purification.  The resin was washed with extraction 
buffer twice to remove unbound protein and the p14 or p14-bombesin was eluted from 
the resin with elution buffer (50 mM sodium phosphate, 300 mM NaCl, 150 mM 
imidazole, 1.6% Igepal, pH 7.0).  The elute was dialyzed against 50 mM HEPES, 150mM 
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NaCl, 1.6% Igepal, pH 7.0) at 4
 o 
C for 12 h and further purified using HiTrap SP HP 
(Sepharose High Performance column) (GE Healthcare) ion exchange columns 
(Amersham Pharmacia Biotech). The column was washed with four different buffers; 
Buffer 1 (50 mM HEPES, 185 mM NaCl, 1.6% Igepal, pH 6.8), Buffer 2 (50 mM 
HEPES, 1 M NaCl, 1.6% Igepal, pH 6.8), Buffer 3 (50 mM HEPES, 185 mM NaCl, 1.6% 
Igepal, pH6.8), Buffer 4 (50mM HEPES, 185 mM NaCl, 1.6% OG, pH 6.8). The p14 or 
p14-bombesin proteins were eluted from the column using 50 mM HEPES, 300 mM 
NaCl (or 450 mM for p14), 1.6% OG. The p14 or p14-bombesin concentration was 
determined by the BIO-RAD DC protein assay (BIO-RAD) and routinely adjusted to 
approximately 1 to 1. 5 mg/ml. The purity of the proteins and N-terminal myristoylation 
was estimated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) using silver stained 12% polyacrylamide gels.  
 
Protein Fusion Assay 
The QM5 cells were seeded at approximately 80% confluency in a 12 well plates and 
allowed to adhere overnight.  4 µg of purified protein (p14 and p14-bombesin) was 
delivered using 3µl Lipofectamine (Invitrogen) for 4 hours in serum free conditions.  The 
media was replaced with fresh supplemented media and incubated for 4 hours till the 
assay is complete.  The syncytia formation was visualized in a similar technique as the 
vector fusion assay using CellTracker™ Green. 
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Assembly of Liposomes 
All lipids were purchased from Avanti Polar Lipids Inc.; 1, 2-dioleoyl-sn-glycerol-3 
phosphatidylcholine (DOPC), 1, 2-dioleoyl-sn-glycerol-3 phosphatidylethanolamine 
(DOPE), dimethylaminoethane-carbamoyl cholesterol (DC-chol) and cholesterol (chol). 
Liposomes were prepared by mixing lipids dissolved in chloroform DOPC: DOPE: DC- 
chol: chol, molar ratios of 60:30:4:6 in a round bottom flask with glass beads.  Small 
glass beads were added to ensure even distribution of the lipid film upon rotary 
evaporation. The chloroform was evaporated for 1-2 hours using a vacuum with a rotary 
evaporator devise (Buchi).  The lipid film was rehydrated with 1X PBS or 10 000 MW 
1mg/ml fluorescein isothiocyanate (FITC) (Sigma) diluted in 1X PBS and added to the 
lipid thin film and vigorous shaking (2700rpm) for 1 hour at room temperature.  
 
Sizing 
The Avestin® extrusion apparatus is assembled and washed with methanol to dissolve 
any residual lipids and washed extensively with 1X PBS.  To reduce the particle size the 
liposome emulsion is passed back and forth between the two Hamilton syringes 
containing polycarbonate filters (100nm pore size) 21 times.  Sonication uses sonic 
energy to disrupt liposome emulsions into single membrane liposomes with diameters 90-
120 nm.  Liposome diameter was determined by dynamic light scattering (DLS) and 
ranged from 90-140 nm.  Liposomes were stored at 4
o
C and were used within two weeks. 
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Proteoliposome Preparation 
For a 1 mL liposome preparation we insert 350 g of purified protein into 20 mM 
liposomes (pre-extruded to 100nm using the Avestin Extrusion apparatus) using a 
detergent depletion method. The purified protein is reconstituted into the liposomes by 
mixing equal volumes of n-Octyl b-D-glucopyranoside (OG) (Bioshop) with the protein 
and the liposomes.  The mixture was rocked for 45 minutes at 4°C.  The OG was 
removed with overnight dialyses at 4
o
C (18000 MW cutoff) with 3 changes of PBS and 
Bio-Beads SM-2 Absorbent (BioShop) to remove the residual detergent. 
 
Liposome Uptake Studies 
MDA-231, HT1080, PC3, and BPH cells were plated at 80% confluency in 6 well plates 
and grown overnight.  The cell monolayer was replaced with cold PBS and cooled to 4
o
C 
for 15 min.  The liposomes were incubated on the cells (1mM) at 4
o
C for 60 min.  After 
60 min incubation, the cells were washed with PBS and pre-warmed (37
o
C) for 60 min to 
initiate delivery of liposomal cargo. After 60 min, the cells were collected and analyzed 
depending on the application.  
 
Receptor Blocking 
PC3 cells were incubated with excess free bombesin peptide (Purified in Dr. Len Luyt 
Chemistry lab) 10 min before the liposomal treatments on cells.  
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siRNA 
Dharmacon predesigned sequence for the gastrin releasing peptide receptor (GRPR) 
small interfering RNA (siRNA) was purchased.  20 nM GRPR siRNA was transfected 
with jetPRIME™ (Polyplus) following manufacturer guidelines.  The scrambled siRNA 
used as a negative control siRNA was purchased from Qiagen. 
 
Wrapsomes 
1, 2-dioleoyl-3-trimethylammonium-propane (DOTAP) lipid (~5.6 mM concentration 
determined by the calculation in Appendix B) purchased from Avanti Lipids was added 
to a round bottom flask with 400 µl of chloroform and small glass beads were added to 
ensure even distribution of the lipid film upon rotary evaporation. The chloroform was 
evaporated for 1-2 hours using a vacuum with a rotary evaporator devise.  The lipid film 
was rehydrated with  100-500 µg of pcDNA 3.1-GFP (Midi-prep quality DNA)  diluted 
in 1X PBS  to a final volume of 1ml and vigorous shaking (2700rpm) for 1 hour at room 
temperature. The DOTAP-DNA core was then added during the hydration step of the 
assembly of liposomes described above and the same insertion protocol was used to 
reconstitute p14 protein within the bilayer. 
 
Quantification of DNA Encapsulation 
DNA encapsulation of pcDNA 3.1-GFP in WS was determined using the Quant-iT™ 
Pico green® ds DNA kit (Invitrogen) following manufacturer guidelines.  Heparin 
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sodium salt (Bioshop) was also added to dissociate the DNA from the DOTAP core in 
order for the Pico green® to stain the DNA.  Using the microplate protocol the samples 
were excited at 480 nm and the fluorescence emission intensity was measured at 520 nm 
using a spectrofluorometer.    
 
Wrapsome Transfection 
Human fibrosarcoma (HT1080) cells were seeded in 12 well plates at 60% confluency 
and allowed to adhere over night.  1 µg of standard and p14-wrapsomes pcDNA 3.1-GFP 
were incubated on the cells while Lipofectamine™ was used as a positive control. 
 
Flow Cytometry 
After liposomal treatment, the cells were detached from the surface using trypsin and cell 
suspensions were centrifuged for 1400 rpm for 5 minutes.  Cell pellets were resuspended 
in 1X PBS, centrifuged for another 1400 rpm for 5 minutes before cells were fixed using 
4% formaldehyde solution in 1X PBS for 10 minutes on ice.  Fixed cells were centrifuged 
for 5 min at 1400 rpm.  The fixative solution was then discarded and the pellet was 
washed 2x with 1X PBS.  The cell pellet was resuspended in PBS + 2% FBS and 
analyzed using flow cytometry (Union Biometrica Biosorter).   
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Confocal Microscopy 
The cells were seeded onto glass coverslips at a confluency of 80% and incubated with 
liposomes with the above cargo uptake studies.  The cells were washed and fixed with 
4% formaldehyde solution in PBS for 10 minutes at room temperature. After 2-3 washes 
with PBS, the cells were incubated one hour at room temperature with PBS- 1% BSA 
with or without 0.1% Triton X-100 (BioShop) depending on the need for intact 
membranes.  Nuclear staining with DAPI and actin filaments stained with phalloidin.  
Confocal images were taken using 20x objective or an oil 63x objective in a spinning-
disk confocal microscope, using a specialized instrument (Quorum Technologies) 
comprised of an upright Zeiss Axio Examiner Z1, LUDL filter wheels and large format 
motorized stage, a Yokogawa spinning disk head and a Hamamatsu 9100–12 Image EM 
CCD camera, controlled by Volocity (Improvision).  Fluorescence images were further 
processed and analyzed using Volocity. 
 
Statistical Analysis 
All statistical analysis was performed in GraphPad Prism® with One-Way ANOVA and 
Tukey’s multiple comparisons post-test with a statistical significance p<0.05. 
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Chapter 3  
3 Results 
3.1 Objective 1: Evaluation of Intracellular Delivery of 
Fusogenic Liposomes Formulated with p14-protein 
(non-targeted) 
A syncytia assay of pFastBac-p14 in human cancer cells reveals cell membrane 
expression of p14 which induces cell to cell fusion in HT1080 cells comparable to Vero 
and QM5 cells previously examined 
Calculation of the syncytial index in a time course fusion assay in HT1080 cells 
Prior to developing a targeted fusogenic liposome, testing needed to be complete to verify 
previous studies and to establish standard assays with the native p14 protein.  Preceding 
comprehensive studies characterizing the expression of p14 was successfully conducted 
in Vero and Quail Fibrosarcoma (QM5) cells (Corcoran & Duncan, 2004; Duncan et al., 
2004).  Vero cells were originally isolated from kidney epithelial cells from the African 
green monkey and are commonly used as host cells for growing viruses (Ito et al., 1964).  
Furthermore, QM5 cells lines are one of the preferred cell lines used in the propagation of 
avian reovirus dissemination (Tran et al., 2009).  Duncan et al used Vero and QM5 cells 
when studying the propagation of the reptilian reovirus, discovering multinucleated cell 
formation (syncytia) similarly found with the avian reovirus (Duncan et al., 1996; 
Duncan et al., 2004).  Our first aim was to determine if this phenomenon would occur if 
we transfected a plasmid containing the p14 sequence, pFastBac-p14 (generous gift from 
Dr. Roy Duncan), in a human cancer cell line.  In this study, we discovered that 
expression of p14 in human fibrosarcoma td-tomato (HT1080td-tom) cells also induces 
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syncytia formation comparable to the results Duncan et al demonstrated in Vero and 
QM5 cells (Figure 3.1A) (Duncan et al., 1996; Duncan et al., 2004).  The fluorescent 
microscopy images detail syncytial formation arises at 8hr post transfection (Figure 3.1 
A&B).  The results from Figure 3.1A demonstrate that the rate of syncytia formation is 8-
10 hrs and figure 3.1B is a quantification of the syncytia formation using a manual cell 
counting approach.  By staining the nuclei with DAPI and using a cell line that stably 
expresses a red fluorescent protein (Td-Tomato), we were able to count the number of 
nuclei per syncytium in five random fields of view to determine the number of nuclei 
present in syncytium. 
 
P14 is a responsible for syncytia formation and is surface localized 
To ensure p14 expression is responsible for the cell to cell fusion, immunostaining of 
permeabilized p14-transfected cells revealed numerous punctate regions radiating out to 
the plasma membrane. A p14 polyclonal antibody was used to stain the cells and 
antibody distribution was detected by immunofluorescence microscopy using an Alexa 
Fluor 488 secondary antibody (Figure 3.1 C).  The p14 distribution had high fluorescence 
signal at the cell surface confirming membrane localization of p14 was responsible for 
the fusion of the HT1080 cells resulting in the syncytia formation (Figure 3.1 C).  
These results in HT1080 cells are consistent with previous research in Vero and QM5 
cells confirming that p14 is localized at the cell membrane to induce cell-to-cell fusion 
creating multinucleated cells in vitro (Corcoran & Duncan, 2004).  The rate of syncytium 
formation, however, differs in HT1080 cells.  Corcoran et al demonstrated significant 
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syncytia at 6 hr (Corcoran & Duncan, 2004) whereas we demonstrated significant 
syncytia at 8 hr post transfection.  These findings establish a fusion assay suitable for 
HT1080 cells to test p14 FAST protein expressions and evaluate if the p14 is fusion 
active. 
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Figure 3.1 Expression of p14 plasmid creates multinucleated cells (syncytia).   
A)  Representative images of HT1080-td-tom cells, 4, 6, 8, 12 hr following transfection 
of pFastBac-p14.  The nucleus was stained with a nuclear stain (DAPI) in order to 
identify the number of nuclei per cell (Magnification 20 x).  
B) Quantification of the number of nuclei per syncytia as measured by manual counting 
of the nuclear signal (DAPI) within the HT1080-td-tom cell in the fluorescent images (5 
fields of view).  Syncytia formation was significantly visible after 8hr  post transfection. 
This data is representative of n=2 experiment and results reported as the standard means 
+ standard error. 
C)  Immunofluorescent staining of  permeabilized HT1080 syncytium 8 hr post 
transfection of pFastBac-p14 using a primary p14 antibody followed by an Alex Fluor 
secondary 488 antibody.  The nuclei were stained with DAPI.  The antibody distribution 
was detected by immunofluorescent microscopy and the antibody staining revealed 
intracellular p14 distribution and surface expression. 
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The Insertion of a Fusion Associated Small Transmembrane (FAST) protein into an 
artificial bilayer by detergent depletion method 
 
Our initial investigation was to confirm the intracellular efficacy of fusogenic (p14) 
liposomes compared to standard liposomes (no protein).  Prior studies documented that 
proteoliposomes containing the p14 (FAST) protein mediated liposome-cell fusion 
thereby increasing cytoplasmic delivery independent of endocytosis (Top et al., 2005).  
We utilized the liposome assembly protocol adapted by the Duncan laboratory, with a 
lipid profile containing 1, 2-dioleoyl-sn-glycerol-3 phosphatidylcholine (DOPC), 1, 2-
dioleoyl-sn-glycerol-3 phosphatidylethanolamine (DOPE), dimethylaminoethane-
carbamoyl cholesterol (DC-chol) and cholesterol (chol) in molar ratios of 60:30:4:6 
(Table 3.1) (Top et al., 2005).  The phospholipid composition has significant influence on 
the bilayer fluidity and therefore an appropriate lipid formulation is used to support the 
insertion of p14 (Cladera et al., 1997; Coderch et al., 2000; Top et al., 2005).  Ensuring 
our liposomes resemble cell membranes as closely as possible we include cholesterol, a 
steroid commonly found in biological membranes (Coderch et al., 2000).  Many 
proteoliposomes are assembled by covalent coupling of the protein to the liposomes 
surface which requires harsh chemicals.  However, the insertion of this transmembrane 
protein requires the addition of a detergent to solubilize the protein (Lichtenberg et al., 
1983; Paternostre et al., 1988).  The purified protein was reconstituted into ~100 nm 
diameter liposomes by mixing 0.9 % OG (Appendix A) suspended p14 with liposomes 
presaturated with OG (Cladera et al., 1997; Petri & Wagner, 1979) followed by removal 
of the detergent.  To ensure elimination of the OG detergent, p14-liposomes were 
subjected to SM2 Bio beads during dialysis at 4°C (Rigaud et al., 1988).  To control for 
the addition of the detergent, standard liposomes were also subjected to addition of OG 
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and dialysis even though no protein was inserted.  FITC was added to the thin film during 
hydration as this is the simplest method of encapsulating hydrophilic cargo within the 
liposome core.   To measure the size of the liposomes after protein insertion, dynamic 
light scattering (DLS) was performed.  DLS analysis revealed the size of the liposomes 
with or without the insertion of protein was comparable of 158.9 + 1.7 for standard and 
152.1 + 1.1 for p14 liposomes (Table 3.2).   
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Table 3.1 Lipid Profile for Assembly of p14 Liposomes 
Lipid Desired 
molar 
ratio 
(%) 
Molecular 
Weight 
(g/mol) 
Volume 
of 
Buffer 
(per 
flask) 
(ml) 
Concentration 
of each lipid 
solution 
(mg.ml) 
Desired final 
lipid 
concentration 
(liposomes) 
(mM) 
Amount 
of lipid 
solution 
required 
(μl) 
DOPC 60 786.13 1 25 20 377 
DOPE 30 744.05 1 25 20 179 
Chol 4 386.66 1 25 20 12 
DC-
Chol 
6 501 1 25 20 24 
Total 
% 
100 %   Total 580 
 
 
 
Table 3.2 Particle Size Analysis using Dynamic Light Scattering (DLS) 
Liposome Group Diameter (nm) 
 
Standard 158.9 + 1.7 
P14 152.1 + 1.1 
 
 
 
 
50 
 
P14 liposomes increase intracellular FITC delivery in PC3 cells 
Liposomal uptake studies were performed on PC3 cells, to test the efficiency of the p14 
FITC delivery. Standard (no protein) and fusogenic (p14) liposomes were prepared and 
incubated on the cells for 1hr at 4°C.  The liposome preparations were incubated on the 
cells at 4°C to inhibit endocytosis ensuring the FITC internalization was dependent on the 
p14 fusion ability (Meulendyke et al., 2005).  Liposomes were then washed off and cells 
were returned to 37°C to allow internalization (Leser et al., 1996). Immunofluorescence 
microscopy images (Figure 3.2A) displays a greater green fluorescence signal in the 
cytoplasm of the cells incubated with the p14-liposomes. In contrast, there was a decrease 
in cellular fluorescence when cells were incubated with std liposomes.  To quantify the 
green fluorescent signal in the cytoplasm of the PC3 cells we measured using flow 
cytometry. PC3 cells incubated with p14-liposomes significantly increase the intracellular 
delivery of FITC (p<0.05) (Figure 3.2B).  These uptake studies verify the novel 
mechanism of p14 liposomes and their ability to increase intracellular delivery 
independent of endocytosis.  We repeated the same experiment on two different cell 
lines, breast cancer (MDA-MB231) and human fibroscarcoma (HT1080) cells to ensure 
p14 liposomes increase intracellular delivery on a variety of cancer cells. Appendix B 
demonstrates p14 liposomes increase intracellular delivery to three different human 
cancer cells.  Once confirming the fusogenic potential of p14, we developed a fusogenic 
targeted fusion protein (p14-bombesin) to bind to prostate cancer cells via the GRPR. 
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Figure 3.2 p14-liposomes deliver significantly more FITC to the cytoplasm of PC3 
cells compared to standard liposomes.  
Liposome uptake analysis of FITC, delivered by standard (Std) liposomes (no protein) 
and fusogenic liposomes (p14 protein).  Representative fluorescent images of one field of 
view of PC3 cells at 20 X magnification.  The cells were stained with a nuclear stain 
(DAPI, blue) and an actin filament stain (phalloidin). The green fluorescent signal 
represents the intracellular FITC uptake.  B) Quantification of the fluorescence intensity 
cells using Flow Cytometry.  Fluorescent intensity + standard error of the mean (SEM) is 
shown for the treatments and this data is representative of n=10 experiment.  One way 
ANOVA (P<0.05) Tukey’s Multiple Comparison Test.  
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3.2 Objective 2: The creation of the p14-Bombesin peptide 
and the Evaluation of the Functionality 
Can a targeting ligand be attached to the C-terminus of the p14 protein to serve as a 
targeting molecule for prostate cancer without disrupting the fusogenic capability of the 
p14 protein? 
Following confirmation that p14 increases intracellular delivery, we tested if the C-
terminus will tolerate a targeting peptide.  By creating multifunctional liposomes we 
could increase intracellular delivery and specificity for prostate cancer.   
Using PCR amplification, successful conjugation of bombesin to the C-terminus of p14 
creates a targeted fusogenic construct 
It has been demonstrated that the C-terminus of the p14 protein can tolerate modifications 
without disrupting the N-terminal fusogenic domain (Corcoran & Duncan, 2004; 
Corcoran et al., 2004).  We hypothesized that conjugation of a targeting peptide to the C-
terminus of the p14 protein would create a novel targeted fusogenic protein.  We choose 
bombesin as the targeting peptide because previous studies in our laboratory have 
demonstrated the targeting ability of bombesin to the gastrin releasing peptide receptor 
(GRPR) on prostate cancer cells (Steinmetz et al., 2011).  We generated a p14-bombesin 
fusion protein using polymerase chain reaction (PCR) amplification strategy represented 
in a schematic in Figure 3.3A.  Our strategy involved designing a reverse primer 
containing the entire bombesin sequence.   To confirm the PCR fusion of bombesin to 
p14, a restriction digest was performed using Bam H1 and Xho1 restriction enzymes 
(RE). The bands present in the agarose gel correlate with the respected DNA size of the 
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pFastbac vector (4.7 kbp) and the p14-bombesin sequence (465 bp) (Figure 3.3B).  The 
DNA fragments were confirmed by sequencing at Robarts Research (Appendix C).   
 
Expression of p14-Bombesin induces syncytia formation similar to native p14 
Once we confirmed the p14-bombesin sequence, we tested the ability to induce 
multinucleated syncytium formation similar to the assay we used to test the functionality 
of native p14 in Objective 1.  As an initial step to examine the correlation between the 
rate and extent of syncytium formation, we analyzed the differences between the native 
p14 and the newly created p14-bombesin. Quail fibroblast (QM5) cells were transfected 
with the original pFastBac-p14 vector (positive control) and the pFastBac-p14-Bombesin.  
Visualized using fluorescent microscopy the cells were stained with CellTracker green to 
identify the multinucleated cell bodies.  Both the p14 and p14-bombesin induced 
formation of small syncytia at 6hr post-transfection which increased to larger countable 
syncytia by 8hr (Figure 3.4).   In summary, the addition of the bombesin sequence to the 
C-terminus of p14 did not disrupt the ability to form enlarged multi-nucleated cells.  
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Figure 3.3 Construction of the p14-Bombesin Fusion protein.   
A) Schematic of the creation of the pFastBac-p14-bombesin.  Bombesin was cloned into 
the pFastbac-p14 vector between BamH1 and Xho1 by designing a reverse primer that 
contained the entire bombesin sequence for polymerase chain reaction (PCR) 
amplification. The p14 construct includes two tags: EK enterokinase cleavage site and 
Histidine 6x (his).   
B) PCR analysis of p14-bombesin was verified by digesting pFastBac-p14-bombesin 
using the restriction enzymes (RE) BamH1 and Xho1 and ran on a 0.7% agarose gel in 1x 
Tris/Borate/EDTA buffer (TBE) buffer.  The bands correlate with the digested fragments 
of pFastBac vector (4.7 kbp) and p14-Bombesin (465 bp).  The p14-bombesin sequence 
was confirmed using DNA sequencing technology.   
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Figure 3.4 Expression of p14-bombesin results in syncytia formation similar to p14.   
Epifluorescence imaging of quail muscle (QM5) cells incubated with 1 µg of pFastBac-
p14 and pFastBac-p14-bombesin using Lipofectamine 2000. QM5 syncytia were Cell 
Tracker green stained at 8hr after transfection.  Syncytia formation clearly visible in both 
the p14 and p14-bombesin images. 
 
 
 
56 
 
Calculating the syncytia index using flow cytometry approach  
To determine whether the extent of syncytium formation was greater in pFastBac-p14-
bombesin expression, we developed a high through-put quantitative analysis to measure 
the multinucleated cells by flow cytometry.  To accommodate the large multinucleated 
cells, we utilized a large cell Biosorter to perform our flow cytometry experiments and 
stained the nuclei with Sytox green.  To ensure the quantification was accurate, we 
obtained samples of single events after analyzing by flow cytometry.  The representative 
images in Figures 3.5A display the differences between control and syncytia cells that 
were sorted after the fluorescence was analyzed.  The control cells contain one nucleus 
whereas the syncytia cells contain many nuclei, representative of the green fluorescent 
nuclei (Figure 3.5A).  The flow cytometry quantification establishes no significant 
difference between the syncytia formation produced by p14 or p14-bombesin expression 
(Figure 3.5B).  Even though there is little to know in regard to how these FAST proteins 
induce membrane fusion except for the importance of the N-terminal myristoylation site, 
we now confirm that the modification of the C-terminus of p14 does not alter the rate or 
extent of the syncytium formation.   These results support the finding made by Corcoran 
et al that deletions of the C-terminus do not disrupt the cell-to-cell fusion (Corcoran & 
Duncan, 2004).  However, our finding differed from their study which found the 
deletions delayed the rate of syncytia formation, whereas conjugating bombesin to the C-
terminus of p14, did not change the rate of formation.   
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Figure 3.5 Quantification of syncytia formation in QM5 cells using Flow Cytometry.  
A) Representative images of the multinucleated cells, the QM5 control cells contained 1 
nucleus whereas expression of the p14 and p14-bombesin contained multiple nuclei.  
B) Quantification of the green fluorescent intensity correlates with the number of nuclei 
present.  Expression of p14 and p14-bombesin were not significantly different for 
formation of syncytia.   
58 
 
Purification of p14-bombesin fusion protein requires a two step process to extract 
enough protein  
Cobalt resin has a high affinity for his-tag on p14-bombesin protein 
The baculovirus expressed p14-bombesin was purified in a two step purification process 
(Top et al., 2005).  The p14-bombesin sequence contains a histidine-tag for purification 
purposes.  Histidine is one of the most prominent affinity tags for protein purification 
(Ley, et al., 2011).   To purify p14-bombesin, the crude cell lysate was first incubated 
with the Talon™ cobalt resin for 3hr at 4o C for initial purification to ensure total binding 
of the p14-bombesin-histidine tag.  Cobalt has a high binding affinity to histidine and 
consequently binds to the p14-bombesin protein and other histidine rich proteins from the 
crude sample (Gaberc-Porekar & Menart, 2001). The resin was washed with extraction 
buffer twice to remove unbound protein and the p14-bombesin was eluted from the resin 
with imidazole containing elution buffer.  Imidazole is used to displace the His-tagged 
p14 protein, freeing the p14 protein.  The extraction of the p14-bombesin protein using 
the Talon™ resin was identified by coomassie stain (Figure 3.6A).  To ensure the process 
extracted the p14-bombesin we loaded the extraction from the Talon compared to the 
wash steps to ensure that we extracted all the p14-bombesin (Figure 3.6A). 
 
 
 Ion Exchange Chromatography further purifies p14-bombesin protein for a homogenous 
population 
To further recover the p14-bombesin protein we use a second purification step using an 
ion exchange column (HiTrap Sepharose High Performance).  The ion exchange column 
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contains a strong cation exchange medium to bind our anionic p14-bombesin protein.  
The adsorbed p14-bombesin protein is eluted using buffers varying in pH and ionic 
strength to dislodge the p14-bombesin protein and collect as individual fractions and 
analyzed separately (Appendix D).  We assessed the ion exchange fractions using silver 
stain analysis and comparing p14-bombesin purified protein to the relative migration of 
the standard purified p14 protein (Figure 3.6B).  In the end, approximately a total of 4 mg 
of p14-bomesin protein is purified from a large scale protein batch.  Despite the quantity 
of purified protein, only a portion of the fractions were myristoylated and therefore 
functional.   
 
 
 
 
 
60 
 
 
 
Figure 3.6 Purification of p14-bombesin  
Cell lysates of sf21 cells infected with p14-bombesin baculovirus were purified using 
cobalt Talon® resin and ion exchange chromatography.   
A) Proteins present were resolved by SDS-PAGE and detected by Coomassie after cobalt 
resin.  W1 (First wash of the resin) and the arrow indicates the p14-bombesin ~16 kDa. 
B) Silver Staining after the ion exchange chromatography.  Native p14 protein was used 
as a standard to indicate the relative migration, W1 (first wash of the column) and the 
arrow indicates the purified p14-bombesin. 
61 
 
Analysis of purified p14-bombesin using fusion assay revealed conjugation of 
bombesin to the C-terminus does not disrupt the fusion motif of p14 protein 
FAST proteins mediate synctyium formation and we examined the kinetics of syncytium 
formation of the purified p14-bombesin protein.  To test the functionality of the purified 
p14-bombesin protein, QM5 cells were incubated with p14-bombesin protein delivered 
with Lipofectamine, followed by fluorescence microscopy.  Since expression of the 
pFastBac-p14-bombesin has been confirmed to mediate cell-cell fusion, we performed a 
similar assay to evaluate the functionality of the purified p14-bombesin protein.  
Syncytium formation was assessed by staining the cells with CellTracker Green at 8hr 
post transfection and visualized using fluorescent microscopy (Figure 3.7).  The purified 
p14-bombesin protein demonstrated significant syncytia formation comparable to the 
fusion active standard p14, verifying that the p14-bombesin protein is functional.  These 
results revealed that bombesin conjugated to the C-terminus of p14 did not disrupt the 
ability of p14 to induce cell-to-cell fusion and elucidates that the p14 N-terminus was 
myristylated.  Furthermore, the different protein fractions (Appendix D) were all assayed 
for fusion activity and the representative images in Figure 3.7 was analysis of the E4 p14-
bombesin fraction.  Most commonly protein fractions from E3 to E6 are the functional 
fractions.  However, the assay is perfomed on all fractions to ensure what protein 
fractions are fusion active and therefore myristylated. 
 
62 
 
 
Figure 3.7 Purified p14 and p14-bombesin protein forms multinucleated cells 
confirming the protein is functional.   
Immunofluorescence imaging of QM5 cells incubated with 4 µg of purified p14 or p14-
bombesin protein. Proteins were solubilized in Lipofectamine and incubated on QM5 
cells for 8hr. Syncytia were visualized by staining the nuclei with DAPI (blue) and the 
cytoplasm with cell tracker (green) using epifluorescence microscopy.  This syncytia 
assay verifies that the purified p14-bombesin protein is functional comparable to the p14 
standard.   
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3.3 Objective 3: Assembly of Targeted Liposomes and 
assessment of FITC delivery to Prostate Cancer Cells 
 
Targeted Liposomes Increase uptake of FITC in Prostate Cancer Cells In Vitro 
The purpose of this study was to validate our hypothesis that bombesin decorated 
liposomes allow target recognition to prostate cancer (PC3) cells.  The targeted fusogenic 
liposomes were assembled in the same manner as the p14-liposomes were in section 3.1.  
For targeted delivery systems to be effective, the target should be up regulated on the 
cancer cells of interest.  Human PC-3 cells are a well studied cell line for gastrin 
releasing peptide receptor (GRPR) targeting because they express approximately 48000 
receptors per cell. To evaluate the targeted fusogenic properties of the p14-bombesin 
protein-containing liposomes, we encapsulated a fluorescein isothiocyanate (FITC) (1 
mg/mL) inside cationic liposomes, standard (no protein), fusogenic (p14 protein) and 
targeted fusogenic (p14-bombesin protein).  We incubated the liposomes on PC3 cells for 
1hr at 4
0
C and measured the uptake of FITC using confocal microscopy and flow 
cytometry.  Figure 3.8 is representative fluorescent confocal microscopy images of PC3 
cells and the green fluorescence (FITC) intensity is indicative of the efficiency of the 
different treatment groups as the targeted (p14-bombesin) liposomes exhibit a greater 
distinction in the cytoplasm of the PC3 cells.  Untargeted liposomal treatments had 
significantly less FITC accumulation in PC3 cells (Figure 3.8).  According to Figure 3.8, 
targeted liposomes significantly increase the FITC uptake into PC3 cells compared to 
both standard liposomes (no protein) and fusogenic liposomes (p14) (P<0.05).  
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Furthermore, p14-liposomes also had significantly more FITC compared to standard 
liposomes, confirming that p14 increases the intracellular delivery.    
The flow cytometry results were reflected in the fluorescence images captured by the 
confocal microscopy.  Flow cytometry histograms are presented in Figure 3.9A and the 
quantification in Figure 3.9B reveals the FITC expression is very consistent with the 
fluorescent microscopy images.  In summary the GRPR are an attractive target for the 
navigation of therapeutics because the receptors are widely expressed on the surface of 
prostatic cancers. Moreover, these results establish that the addition of bombesin peptide 
to p14-liposomes enables successful targeting of PC3 cells increasing the intracellular 
delivery beyond that of the fusogenic liposomes.   
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Figure 3.8 p14-bombesin liposomes increase the intracellular delivery of FITC to 
PC3 cells.  
Fluorescence confocal microscopy images of p14-bombesin, p14, or standard liposomes 
encapsulating FITC incubated with PC-3 prostate cancer cells. Nucleus (DAPI stain) and 
actin filaments (phalloidin stain). These images were taken at 63 x magnification with an 
oil surface.   
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Figure 3.9  p14-Bombesin Liposomes Significantly Increase FITC in PC3 cells 
A) Histogram of FITC signal using flow cytometry of PC3 cells incubated with 
liposomes. B) Quantification of uptake of liposomes into PC3 cells using flow cytometry.  
Mean percentage of the green fluorescent positive cells +standard error of the mean 
(SEM) is shown for each treatment. P14-bombesin is take up more efficiently than p14-
liposomes (p<0.05). This flow cytometry data is representative of n=8 experiment with at 
least 10000 events collected.  One way ANOVA (P<0.05): Tukey’s Multiple Comparison 
Test.  
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P14-Liposomes are internalized within PC3 cells and not bound to the cell surface 
The previous study we studied the binding and uptake of the p14-bombesin liposomes to 
PC3 cells by measuring the fluorescence of the cell with flow cytometry.  However, this 
method does not definitely distinguish between the liposomes bound to the surface or 
intracellularly.  Using confocal microscopy and imaging using 3D stacks, we were able to 
distinguish the localization of the FITC in PC3 cells following p14-bombesin liposomal 
treatment.  The 3D representative images in Figure 3.10 demonstrate the presence of the 
FITC (green fluorescence) located between the actin filaments of the cell membrane 
(orange fluorescence) confirming the internalization of the FITC. Attachment of the 
bombesin peptide did not alter the p14 ability to induce liposomes to cell fusion allowing 
direct cargo delivery to the cytoplasm of the cells.    
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Figure 3.10 p14-Bombesin Liposomes Deliver FITC Intracellularly into Prostate 
Cancer Cells (PC3 cells). 
Fluorescence confocal microscopy 3-dimensional images of p14-bombesin liposomes 
incubated on PC3 cells.  A) Separate channels; green (FITC), orange (actin filaments of 
the cytoplasm), blue (nuclear stain) B) the orientation of the cross-section C) Cross-
section (confocal z stack) demonstrating the intracellular FITC signal. 
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3.4 Objective 4: Evaluation of the Specificity of Bombesin 
Targeted Liposomes 
 
Testing the uptake of Targeted Liposomes on Benign Prostatic Hyperplasia cells  
After we established p14-bombesin liposomes significantly increased the FITC uptake in 
PC3 cells, we determined if this targeting is explicit for cells with a high density of 
GRPR.  To verify the expression of GRPR we used Western blot analysis in different 
prostate cells, human prostate cancer cell line (PC3) and a non-cancerous benign prostatic 
hyperplasia (BPH) cell (Figure 3.11A).  Bands of tubulin were used as a loading control 
for the normalization of the GRPR bands.  PC3 cells demonstrated a higher expression of 
the GRPR compared to the BPH cells, verifying that the PC3 cells were an adequate cell 
line to test the targeting potential of the p14-bombesin liposomes. Since BPH cells have a 
lower GRPR protein expression (Figure 3.11A); we used these cells to perform the same 
experiment as we did on the PC3 cells which over expressed the receptor.  The uptake of 
FITC liposomes in BPH cells, with no protein, p14, or p14-bombesin was evaluated by 
flow cytometry (Figure 3.11B).  Compared to the analysis in PC3 cells, the uptake in 
BPH cells differed only in the p14-bombesin treatment. There was a significant decrease 
in FITC uptake of the p14-bombesin liposomes in contrast to the p14 liposomes (p<0.05).  
This is due to the lower GRPR expression in the BPH cells and therefore the p14-
bombesin liposomes did not bind to the BPH cells at the same efficiency as they did on 
PC3 cells which exhibited a higher receptor density.  Furthermore, the standard and p14 
liposomes had similar FITC uptake comparable to PC3 cells.  This is the first evidence 
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that supports the hypothesis that p14-bombesin liposomes show an increased avidity for 
GRPR expressing PC3 cells.  
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Figure 3.11 p14-Bombesin Liposomes Did Not Target Benign Prostatic Hyperplasia 
Cells  
A) Western blot analysis of the protein expression of the gastrin releasing peptide 
receptor (GRPR) in prostate cancer cells (PC3) and the benign hyperplasia cells (BPH) 
and tubulin was used a loading control.   
B) Quantification of uptake of the liposomes into PC3 cells using flow cytometry.  Mean 
fluorescent intensity + standard error of the mean (SEM) is shown for each treatment.  
P14-bombesin liposomes are taken up less efficiently in BPH cells which have a lower 
protein expression of the receptor, than PC3 cells. This flow cytometry data is 
representative of n=5 experiment with at least 10,000 events collected.  One way 
ANOVA (P<0.05): Tukey’s Multiple Comparison Test. 
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Receptor blocking decreased liposomes decorated with bombesin to PC3 cells  
To dissect the targeting ability, in more detail, we performed a receptor block analysis.  
We have previously reported the bombesin peptide manufactured by the Luyt lab is 
specific for the GRPR (Steinmetz, et al., 2011). To ensure that the ligand was mediating 
the binding of the peptide functionalized fusogenic liposomes to prostate cancer cells, 
PC3 cells were incubated with an excess of free bombesin peptide for 10 min prior to 
incubation with the liposomes. Flow cytometry analysis resulted in a significant decrease 
in uptake of the p14-bombesin liposomes in PC3 cells (P<0.05) (Figure 3.12).  In 
addition, adding the free bombesin peptide to cells incubated with standard and p14 
liposomes did not change the uptake of FITC.  The flow cytometry results indicate free 
bombesin peptide effectively blocks the functionalized fusogenic liposomes from binding 
to the GRPR in PC3 cells, supporting the hypothesis that p14-bombesin liposomes 
specifically target prostate cancer cells.  
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Figure 3.12 Receptor Blocking 
Quantification of uptake of liposomal FITC into PC3 cells using flow cytometry.  P14-
bombesin liposomes were effectively blocked by an excess of free bombesin peptide, 
however the free bombesin peptide did not change the uptake in the other treatment 
groups (Std and p14). This flow cytometry data is representative of n=2 experiments with 
at least 10 000 events collected, FITC positive cells + standard error of the mean (SEM) 
is shown for each treatment. 
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Knockdown of the GRPR Decreased Liposomes conjugated with Bombesin to PC3 cells  
Furthermore, to display the preferential association for GRPR expressing cells, we 
evaluated the uptake of p14-bombesin liposomes on PC3 cells with a lower GRPR 
expression.  We used small interfering RNA (siRNA) technology to knockdown the 
GRPR in PC3 cells.   Transfecting 20 nM GRPR siRNA we decreased the GRPR 
expression in PC3 cells.  Although the transfection only resulted in partial knockdown, 
validated by Western blot analysis (Figure 3.13A), we can significantly decrease the 
FITC uptake of p14-bombesin liposomes compared to uptake in normal PC3 cells (Figure 
3.13B).  Due to the inability to completely knockdown the receptor, the FITC uptake of 
p14-bombesin liposomes in siRNA transfected PC3 cells remained significantly higher 
than the uptake of p14 liposomes.  Despite this result, the findings demonstrate a decrease 
in uptake once the GRPR protein expression was lowered. Together, these results confirm 
liposomes targeted with bombesin peptide showed a significant preference to associate 
with PC3 target cells over PC3 cells with a lower GRPR expression.   
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Figure 3.13 Knockdown of GRPR in Prostate Cancer cells Decreases p14-Bombesin 
uptake  
A) Western blot analysis of the protein expression of the gastrin releasing peptide 
receptor (GRPR) in prostate cancer cells (PC3) and tubulin was used as a loading control. 
PC3 cells transfected with a negative siRNA and 20 nM of GRPR siRNA.  
B) Quantification of uptake of the liposomes into PC3 cells using flow cytometry.  
Knockdown of the GRPR, using 20 nM siRNA effectively decreased the uptake of the 
p14-bombesin liposomes. This flow cytometry data is representative of n=3 experiment 
with at least 10 000 events collected and FITC positive cells + standard error of the mean 
(SEM) is shown for each treatment.  One way ANOVA (P<0.05): Tukey’s Multiple 
Comparison Test. 
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3.5 Objective 5: Evaluate the Intracellular Delivery of 
Nucleic Acids 
 
WS improves Encapsulation of Nucleic Acids 
In this study, we used a previously described “wrapsome” (WS), designed with a core 
composed of a cationic lipid bilayer DOTAP (1, 2-dioleoyl-3-trimethylammonium-
propane) and pcDNA 3.1-GFP plasmid enveloped in the identical lipid bilayer used in the 
above experiments (Table 3.1).  WS efficiently packages the nucleic acid without 
exposing the negatively charged DNA on the outer surface (Yamauchi, Kusano, Saito, 
Iwata, Nakakura, Kato, Uochi et al., 2006).  We predicted that the addition of the 
DOTAP core would encapsulate more DNA than the lipid formulation we used in 
previous experiments.  In spite of this, we were apprehensive how the p14 protein 
insertion process (detergent depletion) would affect these novel wrapped liposomes or if 
the WS would change the OG %.  We determined that the inner DOTAP core had no 
obvious differences then liposomes without DOTAP, as we used a 0.9% OG for insertion.  
At the start of the preparation, 100 µg of DNA (measured by a spectrometer) diluted in 
1X PBS was added to the dried 5.6 mM DOTAP film.  The DOTAP concentration was 
determined by using a calculation employed to have an equal charge ratio of DNA: 
DOTAP.  Thus, the concentration of DOTAP changes with differing amounts of DNA 
(Appendix E).   
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DNA Quantification with Heparin 
In previous research, the stability of DOTAP-DNA complexes inhibits the interaction of 
DNA binding or intercalating agents (Moret et al., 2001).  Ethidium bromide (EtBr) and 
Picogreen are fluorescent probes commonly employed to quantify DNA by measuring the 
fluorescence intensity.  However, these probes are unable to bind to DNA when 
complexed with DOTAP.  In order to release the DNA from DOTAP, polyanionic 
heparin was assayed.  When heparin was added in a final concentration of 12.5µg/µl 
(determined from Appendix F) both the EtBr and Picogreen could bind to the DNA.  
Agarose gel electrophoresis demonstrated that DNA was released from DOTAP in the 
presence of heparin.  When DNA was mixed with DOTAP the release was 100% whereas 
the release of the DNA encapsulated within the DOTAP core was slightly lower which 
suggests an incomplete release of DNA from the DOTAP (Figure 3.14A).    
Picogreen was used to confirm the above results. Similar fluorescence intensities 
obtained with free DNA and free DNA mixed with DOTAP (Figure 3.14B).  In the 
process of generating DNA encapsulated within DOTAP, we achieved ~75% DNA 
incorporation, similar to the results above (Figure 3.14).  In summary, the DNA was 
efficiently encapsulated suggesting that a charge interaction between the negatively 
charged DNA and positively charged DOTAP assisted the efficiency in loading.  
Moreover, the addition of heparin assisted in the release of DNA from DOTAP to assess 
an approximate amount of DNA encapsulated, however not an exact determination 
(Appendix G). 
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Figure 3.14 Heparin releases DNA from the DOTAP 
A)  Influence of DOTAP on DNA migration in a 0.7% agarose gel containing Ethidium 
Bromide (Et Br).  The free/ naked pCDNA 3.1 GFP migrated normally.  Lanes 2&3, 
pCDNA 3.1 GFP incubated with DOTAP in the same concentration as the GFP 
encapsulated within the DOTAP (lanes 6&7).  The + indicated the addition of 12.5 µg/µl 
Heparin for 10 min prior to adding to the gel.  Once Heparin was added to both DNA 
incubated with DOTAP and DNA encapsulated within DOTAP, the bands had migrated 
and the Et BR was able to bind to the DNA. 
B)  Quantification of pCDNA 3.1 GFP using Pico Green nucleic acid stain measuring the 
fluorescent intensity in the presence of heparin (12.5 µg/µl and 25 µg/µl). 
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Transfection Efficiency of p14-WS 
To assess the distribution of DNA delivered by WS within human fibrosarcoma 
(HT1080) cells, we examined the transfection efficiency of a green fluorescent protein 
(GFP).  Transfections were performed under identical conditions to determine the 
difference between standard and p14 WS compared to a transfection reagent.  We chose 
Lipofectamine as a positive control as it is a cationic lipid reagent commonly used for in 
vitro DNA transfections.  The transfections between p14 and std WS were negligible at 
24hr, resulting in green fluorescence comparable of about 1 GFP positive cell/field of 
view (Figure 3.15). However, at 48hr post transfected p14 observed to have more GFP 
positive cells (Figure 3.16).  As expected, DNA mixed with Lipofectamine had higher 
transfection efficiency. Previous studies revealed that cationic carriers are quite toxic to 
cells. However, it is unknown as to what affect other liposome preparations have on the 
morphology of cells. To test the toxicity of the different liposomal transfection reagents, 
we did not remove the DNA transfection solutions.  Light microscopy was used to 
determine the outcome of the different liposomal treatments on the cell morphology.  
Cells exposed to WS were similar in morphology to control cells, whereas healthy 
looking cells were less apparent following incubation with cationic Lipofetamine (Figure 
3.15). In general, cationic lipids increase unfavorable changes in cellular morphology 
whereas the WS did not subject the cells to toxic effects.  Although this study is limited 
by the lack of statistical data, the preliminary results indicate an efficient method of 
encapsulating negatively charged nucleic acids and transfection efficiency with lowered 
toxic effects.  
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Figure 3.15 24hr GFP Transfection Efficiency 
Human fibrosarcoma (HT1080) cells transfected with GFP plasmid by Lipofectamine 
(positive control), Std WS (no protein), and p14 WS.  Control cells were used a negative 
control.  Representative fluorescent microscopy images at 24 hr post-transfection.  
Transfection reagents were not replaced with fresh medium to visualize the toxicity of the 
reagents.  Lipofectamine reagent clearly changed the morphology of the cells compared 
to control cells. 
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Figure 3.16 48hr Transfection Efficiency of Std and p14 Wrapsomes (WS)  
Representative fluorescent microscopy images of human fibrosarcoma (HT1080) cells 
transfected with GFP plasmid using Std or p14 WS (no protein), and p14 WS at 48hr.   
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Chapter 4  
4 Discussion 
 
4.1 General Discussion and Implications 
 
Prostate cancer remains the most common malignancy in North American men and 
despite current treatment options, such as radical prostatectomy and active surveillance  
the therapeutic choices are limited for preserving the quality of life for patients (Bangma, 
2011; Canadian Cancer Statistics, 2011).  For advanced prostate cancer, chemotherapy is 
an unfavorable treatment option because the cytotoxicity of available drugs gives rise to 
unwanted side effects.  To counteract this predicament, liposome drug vehicles increase 
pharmacokinetics and bioavailability by passive targeting through the EPR effect and 
furthermore, liposomes decrease non-selective toxicity (Matsumura & Maeda, 1986). 
However, apart from recent advancements, liposomal drug delivery is still inadequate for 
efficient intracellular delivery.  A major obstacle for liposomes is the cell membrane 
barrier which encumbers the penetration of particles and ultimately impedes the cargo 
delivery to the cell cytosol.  Consequently, the “fusogenic entities” have only overcome 
this impediment by incorporating different elements which allows the liposomes to 
escape from the natural endosomal pathway.  Endosomal release strategies held great 
promise to increase cytosolic delivery however the results were sub-optimal (Sakurai et 
al., 2011; Zhou & Huang, 1994; Zuhorn et al., 2005).  Despite decades of research, many 
liposome formulations do not penetrate the cell membrane and are limited to entry 
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through endocytosis.  The discovery of p14 liposomes is the first to our knowledge a true 
fusogenic liposome that exhibits fusion capabilities on the cell membrane.  A fusogenic 
liposome carrier would be a beneficial means to deliver therapeutics that could be taken 
to the clinics. Studies involving the p14 protein reconstituted into liposomes have 
provided encouraging results in vitro.  In the present study, we report the validation of a 
fusogenic protein, p14, which enhances the intracellular delivery bypassing the 
degradative pathway.  The FAST proteins have exceptional structural features and 
therefore when p14 is reconstituted into an artificial lipid bilayer, the p14 can mediate 
liposomes to cell fusion. We demonstrated that p14 liposomes increased intracellular 
FITC compared to standard liposomes on a variety of human cancer cells.  This 
experiment verified that the uptake was independent of endocytosis predominantly due to 
the fusion motif on p14.  This is in accordance with the experiments conducted by Mader 
et al in which they demonstrated that p14-liposomes increased the LfcinB delivery 
compared to standard liposomes (Mader et al., 2007).  These results concur with the 
proposed mechanism depicted in Figure 1.1 and provide evidence that p14-liposomes 
bypass the endocytic pathway by virtue of the fusogenic domain on the N-terminus of 
P14.  Taken together, the fusion activity of p14 verifies the unique feature of this 
transmembrane protein which increases intracellular delivery but also act as an anchor to 
attach a targeting peptide. 
Prostate cancer targeted nanoparticles conjugated with bombesin have demonstrated both 
in vitro and in vivo active targeting results.  Previous research in our lab has demonstrated 
the feasibility of using the small amphibian tetrapeptide to target nanoparticles to human 
prostate cancer cells in vitro. We have also established anti-tumour activity of targeted 
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particles in an avian embryo model of PC3 cells (Steinmetz et al., 2011).  Therefore, 
active targeting via the bombesin peptide may provide the assistance to overcome hurdles 
facing therapeutic delivery to prostate cancer.  Taken together, we decided to combine 
the two objectives of research in a single moiety to evaluate the potential of PC3 specific 
p14-bombesin peptide as a navigating ligand.  The justification behind the use of the two 
unique entities lies in the caveats outlined in the introduction.  Liposomes assembled in 
this study contained a fusogenic domain allowing direct entry into the cell bypassing the 
endosomal uptake and secondly, liposomes were decorated with bombesin to actively 
target prostate cancer cells.  Furthermore, bombesin did not require chemical conjugation 
for attachment to the liposomes surface.  Instead the transmembrane p14-bombesin 
protein was inserted directly into the artificial bilayer.  
Liposomes functionalized with a targeting moiety have great potential to achieve tissue 
and organ targeting.  A key challenge in development of targeted liposomes is the 
capacity to attach and display the targeting entity on the particle.  The ultimate goal of the 
project was to create a targeted-FAST peptide that would not disrupt the fusogenic 
properties of the p14 protein, but would target prostate cancer cells as well.  For the first 
time, we present a detailed report on how to develop a p14 targeted protein to incorporate 
into liposomes. Evidence demonstrates that attachment of bombesin to the C-terminus of 
the p14 protein does not disrupt the functional capability and supports the findings found 
by Corcoran et al in the deletion studies of the C-terminus (Corcoran et al., 2004).  
However, unlike Corcoran et al who recognized that deletion of amino acids at the C-
terminus decreased the rate of syncytium, we discovered that conjugation of bombesin to 
the C-terminus did not (Corcoran et al., 2004).  P14-bombesin was able to create syncytia 
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in both functionality tests; vector transfection and protein assays.  Furthermore, the 
attachment of bombesin did not change the properties of protein insertion and therefore 
the original OG detergent depletion method was used.  Moreover, the SM2 Bio Beads 
used during dialysis did not inactivate the fusion moiety of p14 as Metsikko et al 
indicated in their study (Metsikko et al., 1986).  Giving rise to the concept, that the C-
terminus of p14 will tolerate the conjugation of a targeting peptide without destroying the 
fusogenic capability of the p14 FAST protein. Thus, p14 is a promising asset to targeted 
liposomal therapy, due to its tolerance of a targeting entity on the C-terminus. 
We hypothesized that anti cancer therapeutics delivered in molecular targeted fusogenic 
liposomes will increase intracellular delivery and specificity for prostate cancer cells.  
Indeed, we found that the p14-bombesin liposomes did target PC3 cells specifically 
compared to non-cancerous BPH cells.  In addition, bombesin conferred specific binding 
to the GRPR verified by receptor blocking analysis and silencing of the receptor.  
Although the methodology employed was not completely novel, the attachment of a 
targeting peptide to the p14 was a distinct feature.  While fusogenic liposomes have 
provided an efficient tool for intracellular delivery, the incorporation of a targeting 
peptide allows for specific tissue and organ trafficking.  In this study, we have engineered 
a functional navigating drug delivery system capable of targeting the GRPR expressing 
cells which is further strengthened by efficient intracellular delivery via the functional 
p14. 
Delivery of DNA and siRNA has gained the attention of many researchers. The 
possibility to transport these nucleic acids would create a new generation of therapeutics. 
DNA vaccines have been used for decades, however if an adequate carrier could shield 
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the DNA from degradation in vivo the possibilities are endless.  Wrapsomes have 
demonstrated a new class of liposomes possible to efficiently encapsulate the negatively 
charged amino acids.  Herein, we describe preliminary evidence of the use of the 
platform in conjugation with the p14 peptide to further increase the efficacy of this 
delivery module. Wrapped Liposomes involves exploiting the cationic lipid nature to 
bind with the anionic DNA and wrapping this core within another lipid bilayer for 
fabrication of an unique wrapsome.  We in turn capitalized on this distinctive 
encapsulation strategy and inserted our p14 protein to increase the efficacy of WS.  We 
demonstrated that the key potential of WS was to not only entrap enough DNA to exert 
an effect on target cells but to decrease toxicity seen with traditional transfection 
reagents.  Our very early studies indicate the potential of using the p14 protein to increase 
the delivery of nucleic acids.  In this dissertation we provided evidence of delivery of 
DNA, however, the possibility of siRNA delivery is also capable.  Therefore, the advent 
of this nanotechnology has provided key improvements to nucleic acid delivery in hopes 
of contributing to the therapy of human disease. 
 
Limitations 
Although this study has provided in vitro “proof of principle” evidence that p14-
bombesin liposomes target PC3 cells, there are drawbacks associated with the lack of in 
vivo studies. Assessing the active targeting of the liposomes to the prostate cancer in an 
animal model would allow us to conclude that the p14-bombesin liposomes navigate 
specifically to prostate cancer specifically.  The assessment of a therapeutic moiety is 
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needed to test the efficiency of the drug delivery platform.  Finally, in vivo studies should 
be preformed to compare the tumour targeting and tumour growth inhibition.  
 
4.2 Future Directions and Clinical Implications 
 
Based on the above finding, the results of the current study contributed to a novel 
therapeutic platform for specific targeting of prostate cancer as well as successful 
intracellular delivery. These results have demonstrated that a targeting peptide can be 
conjugated to the C-terminus of the p14 protein and therefore creates endless 
opportunities to target other diseases organs and tissues.  Using similar approaches 
baculovirus platforms could express a variety of targeting constructs.  Other examples of 
targeting ligands to conjugate to p14 are Rb_p or RGD peptides.  These peptides have 
been investigated to target tumour endothelial cells in angiogenic vessels within solid 
tumours by binding to integrins (Arap et al., 1998).   Using these integrins we could 
target any type of tumour by directing the fusogenic liposomes to the endothelial of 
tumour vessels.  Furthermore, with this therapeutic platform we could create liposomes 
that contained different targeting agents within one liposome population.  Conjugating 
different targeting peptides, such a tumour targeting agent (bombesin) and an angiogenic 
integrin (RGD), liposomes would target both the tumour and the vasculature. 
 Non-invasive imaging would be greatly advantageous to monitor the targeted delivery of 
therapeutic agents as it would allow the real-time evaluation of biodistribution and 
tumour uptake.  Furthermore, non-invasive modalities such as positron emission 
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tomography (PET) and single photon emission computed tomography (SPECT) would be 
useful to image the uptake of liposomes in prostate cancer.  Creation of a dual non-
invasive imaging and drug delivery system using liposomes labeled with radioisotopes 
such as 
111
In. would allow the study of biodistribution of the prostate directed fusogenic 
liposomes using SPECT and/or PET imaging.   
The administration of a gene of interest successfully results in expression of the 
therapeutic protein and thus the delivery of the large anionic DNA across the cell 
membrane is the most difficult endeavours.  Wrapsomes have proved to deliver intact 
anionic nucleic acids and therefore this recombinant DNA technology has created 
opportunities for gene therapy for other diseases such as arteriosclerosis, cystic fibrosis, 
and other genetic disease.  Using this unique lipid formulation that protects the nucleic 
acids from degradation in vivo also allows the opportunity to deliver siRNA.    
Targeted technology encourages earlier deployment of therapeutics to treat prostate 
cancer which can increase the therapeutic index while decreasing side effects.  There is 
an evident need for targeted therapy of prostate cancer to direct therapeutics to the site of 
cancer development.  This research provides preliminary evidence of an effective 
alternative to current liposomal chemotherapy. This targeted fusogenic model would also 
be useful for the administration of other pharmacological agents and could also be used 
for non-invasive imaging.  The targeted fusogenic liposomes engineered in this study has 
the potential to target disease sites while also penetrating the impermeable cell 
membrane, a “Swiss Army Knife” of liposomal carriers. 
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Appendix 
 
 
 
 
Appendix A  Analysis of the % OG need to insert the p14 protein 
Differing concentrations of n-Octyl b-D-glucopyranoside (OG) was added to liposomes 
and the optical density (OD600) was measured.   This assay determines the necessary 
amount of OG to change the fluidity of the lipid membrane without solubilizing the 
liposomes.      
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Appendix B p14-Liposomes increase intracellular FITC delivery 
Liposome uptake analysis of FITC, delivered by standard (Std) liposomes (no protein) 
and fusogenic liposomes (p14 protein).  Representative fluorescent images of one field of 
view of A) MDA-MB-231 and B) HT1080 cells at 20 X magnification.  The cells were 
stained with a nuclear stain (DAPI, blue) and an actin filament stain (phalloidin). The 
green fluorescent signal represents the intracellular FITC uptake.   
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Appendix C Confirmation of the p14-Bombesin Sequence. 
P14-bombesin sequence was confirmed by DNA analysis at Robarts Research Institute.  
The sequence in black corresponds to the original sequence generated by Vector NTI ® 
Software (Invitrogen) including the enterokinase site (purple highlight), histidine tag 
(green highlight), bombesin (yellow highlight) and the stop codon (TAA).  The sequence 
in purple represents the forward sequencing and the green base pairs represents the 
reverse sequence returned from the Robarts.  Verifying bombesin was successfully 
cloned to the C-terminus of p14. 
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Appendix D Silver Stain analysis of the different fractions eluted from the ion 
exchange column from varying the ionic strength and pH of the buffers. 
Aliquots 7 ug of protein (per elution) were analyzed using SDS-PAGE and protein bands 
were visualized by silver staining.  Native p14 was used as a standard (p14 std) to 
indicate the relative migration.  Lanes E4 – E8 show typical elution profile of purified 
p14-bombesin.    
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Appendix E  Calculation to determine the concentration of DOTAP to the amount 
of DNA present to result in a 1:1 ratio 
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Appendix F Determination of heparin concentration to displace DNA from the 
DOTAP using PicoGreen fluorescent analysis 
Increasing the concentration of heparin to 125 μg/μl did not increase the amount of DNA 
released from the DOTAP core compared to 8μg/μl.  Any concentration from 8-125 μg/μl 
will sufficiently displace DOTAP exposing DNA to bind to fluorescent probes for 
quantification. 
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Appendix G Calculating DNA encapsulation efficiency in WS 
Picogreen DNA analysis using heparin to displace DOTAP from the DNA, WS had 
~50% encapsulation efficiency.  This assay is not qualitative as the displacement of 
DOTAP is not definite and thus remains to interfere with the assay.   
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